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1. Hepatitis A virus (HAV) binds to a variety of cell types, and agglutinates 
red blood cells. Binding of the virus to a susceptible cell line, FRhK-4, is 
saturable and exhibits positive cooperativity, with a Hill coefficient of 2.10. 
The sedimentation rate of HAV on a sucrose gradient is increased by 
preincubation with solubilized FRhK-4 cells, indicating the isolation of a virus 
- receptor complex.
2. Two HAV - specific monoclonal antibodies inhibited haemagglutination, 
virus infection of FRhK-4 cells, and virus binding to FRhK-4 cells. A third 
HAV - specific monoclonal antibody failed to inhibit haemagglutination and 
virus infection of an FRhK-4 cell monolayer, but inhibited binding of virus to 
FRhK-4 cells. The two neutralizing monoclonal antibodies competed for the 
same site on the virus surface whilst the non - neutralizing monoclonal 
antibody did not.
3. The cellular receptor for HAV on FRhK-4 cells is trypsin sensitive, whilst 
agglutination of red blood cells can be inhibited by a fucose - specific lectin 
from Lotus tetragonolobus, or preincubation of the virus with a fucosylated 
glycoprotein, thyroglobulin. Binding of virus to FRhK-4 cells is not inhibited 
by a fucose - specific lectin.
1 .INTRODUCTION
1.1 HEPATITIS A VIRUS (HAV)
1.1.1 History
The first recorded occurrences of hepatitis due to an infection with the 
Hepatitis A virus were in the 17^ and 18th centuries, the earliest o f which was 
in Minorca, Spain in 1745 (Hirsh, 1886). Reports o f ’epidemic jaundice’ 
however, go as far back as the writings of Hippocrates, and ancient China 
(Zuckerman, 1983). The disease has most commonly been associated with 
military campaigns, as a result of the fall in standards of hygiene, indeed the 
disease was so prevalent in the 18th and 19th centuries that it was dubbed 
’Kreigsickterus’ by the German troops and ’jaunisse des camps’ (campaign 
jaundice) by the French.
Early clinicians assumed that the symptoms were due to hepatic obstruction 
until it began to be recognized to be as a result o f an infectious agent. This 
view was advanced by Weil in 1886 when he described a severe form, known 
as infectious jaundice caused by leptospires, as opposed to the milder cases of 
epidemic catarrhal jaundice. It was MacDonald in 1908 who finally proposed 
that the disease was caused by a virus acting on a ’’previously damaged liver" 
(McDonald, 1908). The epidemiological studies of Blumer in 1927 established 
the existence of an infection caused by what we now know as Hepatitis A 
virus, while studies conducted by scientists during World War II on human 
volunteers established separate HAV and HBV infections by attempting to 
cross - protect with convalescent sera (Findlay and Willcox, 1945; Oliphantet 
al, 1943).
In 1947 the terms, 'Hepatitis A' to describe epidemic jaundice and 'Hepatitis B' 
to describe homologous serum jaundice were introduced by MacCallum 
(1947), terms which have since been adopted by the World Health
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Organization (W.H.O. 1973; 1977 ). Between the late 1950's and early 1970fs 
seroepidemiological studies further defined the relationship between Hepatitis 
A and Hepatitis B infections, with the causative virus of hepatitis A finally 
being identified in 1973 (Feinstone et al). Since then sensitive immunoassays 
have been developed that can detect the presence of HAV, and in 1979 
Provost and Hillman were successful in cultivating HAV in tissue culture, 
laying the foundations for more extensive studies of the virus.
1.1.2 Epidemiology
In many parts of the world HAV is still endemic, whilst recurrent epidemics 
are a feature of the developed and developing world. In the U.S. A there are 
approximately 22 reported cases of viral hepatitis per 100,000 total population; 
44% of these are as a result of HAV infection, 45% HBV infection, 5%non- 
A, non-B infection (Hepatitis C virus, Hepatitis E virus) and 6% unknown 
(MMWR, 1988). These figures however, represent only a fraction of the total 
infected, the others remaining unreported as a result of relatively mild 
symptoms (Koff et al, 1973,Marier, 1977 ). In many countries HAV epidemics 
follow approximate seven - year cycles reflecting the ebb - and - flow of 
susceptibility within a population. In temperate regions HAV distribution also 
follows seasonal variations, with a higher incidence of infection during the 
Autumn and Winter months. The figures for this pattern however, are easily 
distorted by epidemics and the influx of tourists, but the reason for seasonal 
changes have yet to be explained. The age distribution of a population must 
also be noted. Studies have shown that where sanitation is poor and living 
conditions crowded, close to 100% of children are infected and therefore 
acquire life - long immunity, often with little or no symptoms (Ajdukiewicz et 
al, 1979; Barin et al, 1980; Frosner et al, 1979; Gust et al, 1979; Hilleman et 
al, 1975; Maynard et al, 1976; Szmuness et al 1976; 1977). As a result, 
though the virus is prevalent in these countries, it represents a major health 
hazard only to those travelling in from elsewhere. However, in developed and
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developing nations, as sanitation improves fewer children are being infected 
and do not acquire a natural immunity, and the population is therefore left 
unprotected against a challenge from the virus, and epidemics may occur. 
Several factors have been identified as posing a particular risk and require 
special emphasis. In the U.S.A. young children attending day - care centres 
often pass the virus from one to another, and subsequently carry it home to 
parents and older siblings (Hadler et al, 1980; Benesonetal, 1980) Sexual 
transmission amongst homosexual men also represents a problem, with an 
annual seroconversion rate of 22% noted in a study in Seattle, Washington 
(Corey and Holmes, 1980). In the developing and under - developed world 
transmission as a result of the consumption of food, particularly shellfish 
harvested from water contaminated with human faeces is an important cause, 
especially since the shellfish are able to concentrate enteroviruses by up to 60 - 
fold and are often eaten raw (Mitchell et al, 1966). It was thought that water - 
borne infections accounted for a proportion of infections but since the 
identification of the hepatitis E virus these figures have to be treated with 
extreme caution (Khuroo, 1980). HAV is rarely transmitted by blood - to - 
blood contact, in fact the prevalence of anti - HAV antibodies in patients with 
a history of multiple transfusions is no higher than for others of a similar 
socioeconomic background without such exposure (Papavangelou et al, 1978; 
Stevens et al, 1978). This is almost certainly due to the very brief viraemia of 
between 7 - 1 0  days that occurs 1 - 2  weeks prior to clinical symptoms.
The principal mode of transmission for the virus is the faecal - oral route, 
although subcutaneous inoculation may also lead to infection with little or no 
variation in resulting incubation time or concentration of viral shedding. The 
route by which the virus enters the liver remains unresolved, although it has 
been detected by specific mAbs and cDNA probes in various tissues including 
intestinal, lymph and kidney (Fagan et al, 1990), suggesting that replication 
in the jejunum prior to transmission via the portal vein may occur (Gust,
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1988). HAV is shed in the faeces 3 - 1 0  days before the onset of clinical 
symptoms, which occurs after an incubation period of around 28 days. This 
shedding of virus occurs at approximately the same time as, or marginally 
before, an increase in ALT (alanine aminotransferase)levels, indicating liver 
damage. Communicability of the infection is at its highest during this period. 
The presence of HAVAg in the bile of infected chimpanzees during viral 
shedding indicates that this is the method by which virus passes from the liver 
to the gut (Schulman et al,1976).
1.1.3 Pathology
The infection manifests itself in varying degrees of severity. As has already 
been mentioned, in young children the condition may be totally symptomless, 
while in other cases symptoms such as nausea, jaundice, diarrhoea, dark 
urine, abdominal pain, malaise, fever and myalgia may occur to varying 
degrees. Unlike other causative agents of viral hepatitis, HAV is not known to 
cause persistent infections, although 10% of cases follow a protracted course of 
up to 9 months. In a very limited number of adult cases fulminant viral 
hepatitis A can occur (Rakelaetal, 1978; Mathiesen et al, 1980) potentially 
leading to coma and death.
It now seems certain that the symptoms of this infection are not as a result of a 
direct cytopathic effect o f the virus, but mainly occur via a T - cell mediated 
immunopathological mechanism (Kurane et al, 1985). This can be shown by 
the lack of cytolytic effect o f HAV on tissue culture fibroblasts (Valbracht et 
al, 1986), the increase in macrophages in the liver biopsies following infection 
and parallels with the recognized immunopathology of HBV infection.
1.1.4 Immune response and serological diagnoses
An increase in the total levels of serum immunoglobulins is common during 
acute HAV infections (fig. 1.1) and may include antibodies to HAV as well as 
to gut bacteria and other unrelated antigens. The reason for such a non - 
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Fig. 1.1 Clinical course of HAV infection in a human volunteer given an oral 
inoculum of the MS-1 strain of virus.
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certainly present by the onset of symptoms (Lemon et al, 1980; Rakelaetal, 
1977; Decker et al, 1979; Locamini et al, 1977)) and reaches a peak titre 1 - 
2 weeks later. A number of assays have been developed to detect these serum 
antibodies, including immunoelectron microscopy (Feinstone et al, 1973), 
complement fixation (Provost et al, 1975a), radioimmunoassay (Hollinger et 
al, 1975) and enzyme immunoassay (Locamini et al, 1978). The IgM 
response is typically short - lived ,and was first detected by immunoelectron 
microscopy by Locamini (1974) and subsequently by various serological assays 
(Locamini et al, 1977; 1979). IgM is replaced with IgG and IgA which first 
appear as part of the total immunoglobulin response. Serum IgG persists for 
long periods of time, perhaps for life, although levels may drop below those 
detectable by current methods (Ajdukiewicz et al, 1979; Villarejos et al, 
1982). If challenged with HAV a second time, an immediate IgG response 
ensues, devoid of IgM, usually resulting in an asymptomatic infection 
(Villarejos, 1982). The success of passively administered immunoglobulin 
suggests that this IgG response to HAV is primarily involved in protection 
against a second challenge from the vims, and that it is more likely to be other 
immune mechanisms, such as interferon's, natural - killer cell activity and T - 
cell cytotoxity which is responsible for controlling a primary infection.
Though IgA is known to be present in faecal samples from infected individuals, 
its role in immunity is unknown.
1.1.5 Therapy and prophylaxis
Treatment of HAV infections is usually supportive, with a recommendation of 
bed rest and a high calorie diet. It is probable that corticosteroids accelerate the 
recovery from late cholestasis (Gordon et al, 1984) although a small study 
using methyl - prednisolone indicated a substantially higher mortality in treated 
patients as opposed to those given a placebo (Gregory et al, 1976). The vims 
appears to be resistant to most established anti - viral drugs but various agents 
are being evaluated in tissue culture. Amantadine and ribavirin are two
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showing sufficient promise to warrant clinical trials (Passagot et al, 1988). 
Interferons have also been shown to be effective in vitro (Vallbracht et al,
1984) which is of particular relevance since HAV is a poor interferon inducer 
(Vallbracht et al,1985).
Prevention of HAV infection is essentially dependent on high standards of 
hygiene particularly clean, chlorinated drinking water and the supervision of 
food and water handlers. Transmission within families, even in the western 
world, remains high with rates as high as 20%. Barrier nursing is not required 
in hospitalized cases and only in neonatal nurseries must particular care be 
taken. In general HAV is not considered to be an occupational hazard. In the 
laboratory, spillages represent a theoretical risk and therefore the use o f  
cabinets to contain aerosols is justified. The 60 - fold concentration increase of 
HAV in shellfish from the surrounding water, as a result of the large 
throughput of oxygenated water, represents another area where hygiene 
methods can be improved. Presently the industry standard is a total 
replacement o f water in shellfish beds every 2 -3 days. This is clearly 
insufficient, since studies have indicated that HAV particles can remain in 
these tanks for up to 5 days (Sobsey et al, 1988). Limited protection from 
infection by HAV, of around 3 months, can be conferred by the intramuscular 
injection of normal pooled immunoglobulin (NPIG). This relies on the 
prevalence of anti - HAV immunoglobulins in the normal pooled sera to protect 
the immunized individual. There is the possibility o f spread of HAV by 
passive immunization, but the effects are highly attenuated and may indeed 
result in life - long immunity, though this must never be assumed. There have 
also been no recorded cases of infection from other organisms following use of 
this preparation since it is prepared by Cohn ethanol fractionation, which is 
one of the safest methods of preparing pooled immunoglobulins for passive 
immunization. This form of protection is normally only administered to 
individuals from non - endemic areas visiting regions with a high incidence of
8
the virus. In the UK. this is extended to any country outside Europe except 
U.S.A., Canada, Australia and New Zealand. In developed countries, post 
exposure passive vaccination is also recommended for household contacts 
during outbreaks.
The main concern with this form of protection is two - fold. Firstly this type of 
vaccination will only protect for 6 months, making it impractical for people 
who may experience multiple exposures. Secondly, as the prevalence o f HAV 
- specific antibodies in the community is reduced, the efficacy of the 
immunization is compromised. Both of these problems have led to the need for 
an improved vaccine
The production of a vaccine, as with many other viruses (most notably 
poliovirus) has been approached in two ways. The first method is the 
preparation of a formaldehyde - killed virus, which at present is the only 
licenced form of HAV vaccine available.
There are however, problems associated with killed vaccines. Firstly the cost 
of production can be very high as a result of the poor growth of HAV in tissue 
culture making the immunization of the whole population impractical.
Secondly, though an effective immunogen, booster injections are likely to be 
required periodically, which may not be necessary with an attenuated vaccine. 
Some doubt lies with the ability of killed vaccines (as with poliovirus Salk 
vaccine) to produce secreted IgA antibodies in the gut, which would insure 
complete neutralization o f the virus and subsequently halt its spread. The 
formalin - inactivated Salk poliovirus vaccine has nevertheless proved to be 
highly effective in the countries of Western Europe where it has been 
exclusively used.
Clearly the most effective way of combating HAV in the long term is the 
introduction of a five attenuated vaccine, as has been so successful with other 
viruses. This would ensure life long effective immunity, would overcome 
many of the production costs involved with the current killed vaccine methods
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(less antigen would be required per inoculaton and less often) and would, if  
necessary instil herd immunity through effective gut IgA production. There are 
however, problems associated with this type of vaccine, as has been shown 
with poliovirus Sabin 3 strain, where reversion to a neurovirulent form takes 
place in the gut and may then be excreted. Infection by neurovirulent 
poliovirus vaccine revertants only occurs, however in 1 in 1 million cases, and 
in the U.S.A. live attenuated vaccines are now the only form used.
There are two groups working on the attenuation of HAV, one at the Merck 
Institute working with strain CR326 and the other at the National Institutes of 
Health working with HM175. Both groups have concentrated on multiple 
passaging of the virus in cell culture.
Recent studies with strain CR326 have produced two pools of cell - culture 
variants named F and F  (Provost et al., 1986). F produced mild elevations in 
serum ALT in 3 of 12 marmosets tested, whereas F  produced no evidence of 
disease at all in 12 of 12 marmosets, yet produced detectable anti - HAV 
antibodies in 10 of the 12 animals. Both sets of marmosets were resistant to a 
challenge of 105 ID50 of wild type virus. In humans, F produced mild elevations 
of ALT in 9 of 25 tested, with F  producing detectable levels of anti - HAV in 
10 out of 11 subjects, with no sign of disease in any. Passage 32 of HM175 
has shown to be attenuated for marmosets, producing only slight increases in 
ALT levels in one of four animals immunized.
Though these results look very promising, certain questions have to be 
answered; can the oral vaccine produce a protective response, is the 
vaccinated subject resistant to oral and intravenous challenge, is the virus 
subsequently secreted in the faeces, can the vaccine revert to virulence and 
will liver function tests be unavoidable?
There are other methods o f vacccine production available. Molecular cloning 
of the HAV genome, and subsequent surface probability plots and homology 
comparisons have allowed the production of small oligopeptides containing
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candidate neutralization sites (Emini et al., 1985). A synthetic peptide 
containing amino acids 11-25 of VP 1 has been used with laboratory animals 
and has produced neutralizing antibody. The response however, was highly 
variable between animals and will require further work to improve 
immunogenicity. HAV encoded proteins have been expressed as fusion 
proteins in E.coli (Ostennayr et al., 1987; Ross et al., 1988; Johnstone et al., 
1988) and in insect cells (Harmon et al., 1988) Two of these proteins 
containing VP1 sequence produced a response to VP1 but failed to produce a 
response to whole virus (Ross et al., 1988; Johnstone et al., 1988). A 
Trp/VPl fusion protein however, was able to prime the immune response such 
that an immune response was elicited against an otherwise subimmunogenic 
concentration of whole virus(Johnstone et al., 1988). As it is now widely 
accepted that the neutralizing sites on the HAV capsid are conformationally 
formed, it is likely that expression of an empty capsid may be necessary to 
produce an effective immune response. Indeed, the maturation of virus 
structure associated with encapsulation of viral RNA may still be required to 
elicit an acceptable response.
1.1.6 Virus structure
The Hepatitis A virus is a small, non - enveloped virus of the family 
Picomaviridae. It was previously classified in the genus enterovirus, but 
certain unique characteristics such, as stability in high temperatures and its 
tendency to establish persistent infections in vitro (Provost and Hilleman,
1979) casts doubt on this classification. With the publication of sequence data 
(Linemayer et al, 1985; Najarian et al, 1985; Baroudy et al, 1985) the 
comparison between HAV and other picomaviruses was extended to genomic 
organization (Palmenberg, 1987, 1989) and it was realized that while 
homology within genera is high, homology between genera is considerably 
less, with HAV sharing less homology than is present between the other 
genera. On this basis HAV has now been placed in its own genus, hepatovirus
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(Francki,1991). Mature virions appear spherical (see fig. 1.2), are 
approximately 27nm in diameter and have icosahedral symmetry (Feinstone et 
al, 1973; Siegletal, 1982). The sedimentation coefficient of the virus is 
156S and the density is 1.32 - 1.34g/cm2 in caesium chloride (Siegl et al, 1981; 
Lemon et al, 1985), with minor populations of viruses having densities of 1.27
- 1.32g/cm2 and 1.39 - 1.50g/cm2 (Coulepis et al, 1982). The 'light' viruses 
probably represent empty capsids (Tratschin et al, 1981; Gauss - Muller et al, 
1986), mature virions associated with lipids (Lemon et al, 1985) or defective 
interfering particles (Garelick et al, 1988). 'Heavy' particles are thought to 
have taken up CsCl during centrifugation (Cooper et al, 1978). The 
proportions of these minor populations may reflect the strain under 
investigation and the purification methods employed. The stability of HAV is 
similar to that of the other picomaviruses except in its ability to withstand 
relatively high temperatures (see Table 1.3). The virus is also stable at a pH of 
3.0 (Siegl et al, 1984) and is resistant to many lipid solvents (Provost et al, 
1975). HAV is however, readily inactivated by formaldehyde, a fact which 
has been utilized in the production of killed active vaccines (Provost and 
Hilleman, 1978). When purified virus was subjected to SDS - PAGE, three 
structural proteins were revealed (Coulepis et al, 1978) with apparent 
molecular weights of 34, 25.5 and 23 kDa, consistent with the three main 
structural proteins of better characterized picomaviruses. Later reports 
identified a putative fourth protein with an approximate weight of 7 - 14kDa 
(Coulepis et al, 1980; Tratschin et al, 1981). Using nucleotide sequence data, 
and alignments with known picomavirus structures, a more detailed analysis of 
the capsid proteins has been possible (Linemayer et al, 1985). The majority of 
the proposed gene locations for the capsid proteins and cleavage junctions have 
now been confirmed by amino acid sequencing (Linemayer et al, 1985; Gauss
- Muller, 1986) and studies with synthetic peptides (Wheeler et al, 1986) with 
only the VP 1/2A junction having been modified as a result of protein
12
Fig 1.2 Electronmicrograph of a Hepatitis A vims particle fixed and stained in 
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Table 1.3 Biophysical characteristics of Hepatitis A Virus compared with 
other picomaviruses.
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sequencing. The predicted molecular weights for the four capsid proteins are 
33.2kDa (VP1), 24.8kDa (VP2), 27.8kDa (VP3) and 2.5kDa (VP4). 
Contradictory SDS-PAGE sizing of the three largest proteins, particularly VP2 
and VP3 was explained by Wheeler et al (1986), who noted that the migration 
of VP2 was significantly affected by the presence of urea in the gel system.
This was confirmed by direct comparison of the two systems using 
immunoblotting techniques using antisera to VP2 and VP3 (Ross, 1988). As 
with the other picomaviruses some vims particles contain a VPO protein, 
which is the precursor protein for VP2 and VP4 (Gauss - Muller et al, 1986; 
Ross, 1988). Though this would suggest that VP4 is generated by the cleavage 
of VPO, though further investigation is required to confirm this. One 
unanswered question is the size of VP4. Consensus sequences have indicated 
that there is a myristylation site similar to that of other picomaviruses at gly- 7. 
This would leave a peptide of only 17 amino acids with a molecular weight of
1.7 kDa which has yet to be detected in virions or infected cells.(Chow et al, 
1987; Palmenberg, 1989)
1.1.7 Antigenic structure
Currently the understanding of the antigenic structure of HAV is very basic. 
This is because attempts to characterize the relevant regions of the capsid have 
been impeded by the slow and generally non - cytopathic replication o f HAV. 
This results in a lack o f X - Ray crystallographic data which is available to 
other picomavirologists. Some progress has been made with the use of 
neutralization escape mutants and peptide immunogens, coupled with 
computer alignments with other picomaviruses.
Although only very few HAV strains have been investigated in depth, it is 
evident that there is no significant antigenic variation between them. This can 
be exhibited in the classical cross neutralization experiment, for instance, 
between strains HM175 recovered from a human in Australia and PA21 
recovered from a New World Owl monkey, where sera raised to one strain
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successfully neutralized the other (Lemon and Binn, 1983). In contrast there 
are marked differences in the RNA sequence in the PI region of these viruses 
which suggests that these viruses are genetically distinct from one another 
(Lemon et al., 1987). This all suggests that the constraints on HAV to 
maintain this antigenic structure are extremely strong.
There is now considerable evidence that the antigenic sites on the HAV capsid 
are created during the assembly and folding of the capsid proteins, rather than 
being sequential immunogens (Gerlich and Frosner, 1983). This can be partly 
demonstrated when attempting to detect denatured capsid proteins with 
neutralizing antibodies on a western blot, where staining does not occur. 
(Hughes, 1985) Moreover it has been shown that individual capsid proteins, 
even those bearing parts of the immunogenic region, elicit very little antibody 
reactive to native capsid. Although the amino acid sequence of HAV and 
poliovirus type 1 have little in common, surface probability profiles o f the N- 
terminal halves o f the two peptides indicate that there may be some higher 
order similarites (Emini et al., 1985; Najarian et al., 1985). Specifically VP 1 
residues 89 - 103 that form the immunogenic "C3 loop” of polio (Hogle et al., 
1985; Minor et al., 1986; Wychowski et al., 1983) may be conserved in 
HAV. Furthermore the HAV VP1 residues 11 - 25, selected because they 
correspond in the surface probability profile to an immunogenic region of 
poliovirus VP1 sequence, elicit a low titre of neutralizing antibody in rabbits 
(Emini et al., 1985). These residues in poliovirus, however are not on the 
capsid surface but may only be externalized when the virus binds to its cellular 
receptor. It is likely, therefore that in HAV these residues do not represent a 
major immunogenic site. Various other attempts have been made to induce an 
antibody response from peptides expressed in E.coli. The N-terminal 60 amino 
acids of HAV VP1 when expressed as a fusion protein with E.coli p - 
galactosidase does appear to be weakly antigenic (Ostermayr et al., 1987). 
Likewise, expression of the entire VP 1 polypeptide with the carboxy-terminal
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46 amino acid of VP3 as a TrpE fusion protein is capable of producing an 
antibody response to denatured VP1 but not intact virus (Johnston et al.,
1988). It is interesting to note that this second polypeptide is capable of 
priming for a neutralizing antibody response to subimmunogenic quantities of 
intact virus, and therefore probably contains relevant T - cell epitopes.
As has been mentioned, one of the more important ways of determining the 
neutralization sites on the HAV capsid is the induction of escape mutants.
These are viable virus mutants which arise as a result of replicating HAV in the 
presence of neutralizing antibodies. As a result, they have altered 
neutralization sites such that the antibodies are no longer able to bind. By 
sequencing their genomes the position of these sites can be established and 
therefore the position o f wild type virus neutralization sites.
Two sites of interest have so far been identified, a G to C change at position 
1677 which results in an amino acid change from Asp70 to His on VP3 and a 
second, apparently a less effective escape mutation, occurs at position 2512 
with a C to T change resulting in a Ser to Leu alteration at amino acid 102 of 
VP1 (Stapleton and Lemon, 1987). These results suggest that Asp70 on Vp3 
represents an important immunogenic site on the HAV capsid and changes at 
this point produce a conformation that the monoclonal antibodies are unable to 
bind to. The alternative, but less likely possibility is that the amino acid 
change stops the monoclonal antibodies binding elsewhere on the capsid by 
global conformational changes. This is made more unlikely by the known 
clustering of escape mutations around the cellular binding site on the poliovirus 
and rhinovirus. Unfortunately for simplicity, the crystal structures of other 
picomaviruses suggest that the two sites mentioned above are in fact distant 
from each other, VP 1-102 lying near the five-fold axis o f symmetry and VP3- 
70 lying at the three-fold axis. There are therefore two possible explanations at 
present, firstly that the structure is not sufficiently similar to other 
picomaviruses to compare, or that indeed the binding of monoclonal
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antibodies at sites distant from the neutralization site can exert changes. This 
second explanation has been shown to be true for FMDV virus.
The neutralization mechanism for HAV is at present unknown.
1.1.8 Molecular Virology
Early observations that HAVAg exists exclusively in the cytoplasm of an 
infected cell provided evidence that HAV was an RNA virus and did not 
reverse transcribe its genome into DNA for integration into the host cells 
genome (Provost et al, 1975; Mathieson et al, 1977). Staining of the particles 
with acridine orange also suggested that the viral genome was single stranded. 
(Provost et al, 1975). In 1981 Coulepis et al showed that the genome was of 
single - stranded RNA containing poly(A). The nucleic acid sedimented at 
35S, with a bouyant density of 1.64g/cm2.
More recently, the cloning of the HAV genome as cDNA from virus purified 
from the liver o f an infected marmoset, has allowed more detailed analysis of 
its makeup (Ticehurst et al,1983). The complete sequence was subsequently 
determined (Baroudy et al, 1985; Cohen et al, 1987) and this remains the 
only wild type sequence published to date. Several sequences, however, have 
been established from virus purified from tissue culture after differing numbers 
of passages (Najarian et al, 1985; Linemayer et al, 1985; Venuti et al, 1985; 
Ross et al, 1986; Cohen et al, 1987; Ostermayr et al, 1987; Jansen et al, 
1988).
Cloning and restriction mapping of the genome have indicated that it is 
approximately 7500 nucleotides long ( Ticehurst et al, 1983 ), consisting of a 
5’ non - coding region of 734 nucleotides, an open reading frame encoding 
2227 amino acids followed by two termination codons, a second, 60 base non 
- coding region and a 3? poly (A) tract (Baroudy et al, 1985; Linemayer et al, 
1985; Najarian et al, 1985). By comparing the predicted amino acid sequence 
for HAV to that of poliovirus type 1 in homology computer programs 
(Najarian et al, 1985), a complete putative polyprotein cleavage map has been
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assembled. Subsequently other programs have been used to predict structural 
and hydrophilic properties of the proteins encoded by the genome and therefore 
to predict possible cleavage sites, most of which are atypical for 
picomaviruses.
In fig 1.4 the genomic organization of HAV is compared with that of poliovirus 
using the L434 nomenclature of Rueckert and Wimmer, (1984). The 
nomenclature divides the genome into regions PI, P2, andP3. The PI 
proteins (1A - ID) represent structural proteins while P2 (2A - 2C) and P3 (3A 
- 3D) are involved in vims replication.
The localization of the genes encoding vims proteins has been partly achieved 
by amino acid sequencing of purified structural proteins. Linemayer et al,
1985 showed that the N - terminus of VP1 mapped to nucleotide 2208 which is 
in agreement with amino acid sequence results from reverse - phase high 
pressure liquid chromatography performed by Gauss - Muller et al, 1986. 
Gauss - Muller et al (1986) also used this method to sequence the N - terminus 
of VP2 to give the same result as that obtained by Cohen et al, (1987).
The localization of the HAV structural proteins have been further characterized 
by successfully reacting sera raised to synthetic oligopeptides representing 
specific areas of the PI region with immunoblotted HAV proteins.(Wheeler et 
al, 1986 b) The location of VPg was established by immunoprecipitating the 
protein from purified vims with antisera raised against oligopeptides 
representing the predicted sequence of VPg.
The non-coding regions of the HAV genome have some notable features.
There is a high proportion of pyrimidines (C+T) near the 5’ terminus of the 
genome (95% of nucleotides 99-138 and 68% of nucleotides 31-249) and it is 
also here where there is most conservation between strains (>95%) This region 
is considered to be analogous to the poly(c) tract seen in cardiovimses.
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Poliovirus 7433 nucleotides
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? VPg donor prolease
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Fig 1.4 Genomic organization for hepatitis A virus and poliovirus (L343 
nomenclature) and the protein processing map of the poliovirus 
polyprotein. Virion RNA is covalently linked to a protein, VPg at the 5' 
end and has a poly (A) tract. Protease 2A cleaves between PI and P2. 
Protease 3C cleaves all other sites exept for 1A/1B, which is 
autocatalytic. PI are structural proteins whilst P2 and P3 perform 
replicative functions.
2 0
In contrast, the 3' terminus of the HAV genome has the highest percentage 
differences between strains, at about 20%, and it is this portion o f the 
sequence which is most often used to differentiate strains.
As with other picomaviruses, the sequence and secondary structure of the 5' 
non - coding region of HAV appears to play an important role in translation. It 
has been known for some time that the 5' NTRs of picomaviruses are well 
conserved, despite the high error frequency normally associated with RNA 
viruses. This suggests that these areas are important for replication, with 
minor base changes in the region having major effects on replication and 
virulence, as has been demonstrated with poliovirus ( Racianello and Meriam, 
1986; Kuhn et al, 1988; Nomoto and Wimmer, 1987). It is likely therefore, 
that picomaviruses have a number o f control elements in this region which 
effect replication, translation and encapsidation. Picomavirus RNA is 
uncapped and contains many noninitiating AUG codons. By a series of 
experiments on EMCV, which involved testing the inhibitory effects o f cDNA 
to various portions of the 5’ NTR, it was found that interfering with the 
extreme 5? end of the genome did not effect translation, whereas hybrdization 
o f the cDNA strands to areas downstream in the putative ribosome entry site 
did (Shih et al, 1987). This internal ribosome entry site (IRES) was further 
demonstrated by investigating the expression of a polycistronic mRNA 
containing non - overlapping open reading frames (ORF)(Jang et al, 1988;
Jang et al, 1989; Pelletier and Sonenberg, 1988). The 5TSTTR of either 
EMCV or poliovirus was inserted between ORF, resulting in the cap 
independent translation o f the adjacent downstream ORF. In frame mutation of 
this picomavirus NTR resulted in extremely poor translation of the adjacent 
sequences.
Work is continuing to identify the IRES in various picomaviruses and to 
investigate its structure. The sequencing of the HAV 5' NTR has indicated that 
the same structures exist as with other picomaviruses. Brown et al, (1991)
21
have used a phylogenetic approach in developing a secondary structure for the 
5’ NTR. According to this model the 5tNTR contains six major domains, 
including a hairpin loop at the 5’ terminus, a long single polypyrimidine tract, 
and two large stem loop structures with multiple covariant mutations located 
between bases 324 and 692. The stem loops share several motifs with EMCV. 
A rabbit reticulocyte lysate system was used to investigate expression under 
various reduced versions of the 5' NTR of HAV. It was established that 
removal of nucleotide (nt) 1 to 354 had little effect on translation, while 
deletion up to nt 457 resulted in decreased translation. Deletion up to nt 533 
completely abolished translation . Further deletion, to nt 633 increased 
translation again to a level greater than the full - length R N A .. This suggests 
that the sequence 3' to base nt 355 plays a vital role in the translation of 
genomic length RNA.
1.1.9 Replication of HAV in Tissue Culture
It was not until 1979 that Provost and Hilleman first isolated HAV. This delay 
was due to problems associated with culturing the virus, such as its unusually 
long replication time, the resulting contamination from other viruses, and the 
difficulty of detecting the virus in the absence of cytopathic effect.
The problem of slow replication still remains, but the detection of HAV has 
improved considerably, with the immunofluorescence assay of Mathiesen et al, 
(1977) which Provost and Hilleman used. HAV strain CR326 which had been 
passaged multiple times in Sanguinis mystax and Sanguinis labiatus 
marmosets was inoculated into explant cultures of S. labiatus liver tissue.
Within 8 days cells showed evidence of infection, and after 23 days the 
majority o f cells showed immunofluorescent staining of HAVAg. Following 
this the virus was passaged in FRhK-6 cells but with no cytopathic effect. 
Subsequently, others demonstrated adaptation to cell culture without prior 
passaging through marmosets. (Frosner et al, 1979b; Balayan et al, 1979; 
Daemeretal, 1981; Locamini et al, 1981). Flehmig et al (1980; 1981)
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established a line o f persistently infected FRhK-4 cells which eventually 
resulted in the realization that, unlike other picomaviruses, persistent 
infection with HAV can result in constant low level production of HAVAg with 
no effect on host cell morphology and synthesis o f macromolecules (Gust and 
Feinstone, 1988). Only recently have strains been produced, through multiple 
serial passaging, that have sufficiently short replication times to allow full 
studies of the kinetics of HAV replication.
In 1985 another important breakthrough in the study of HAV took place.
Venuti et al reported the isolation of an HAV strain which caused cytopathic 
effect after 7 - 1 0  days, a result that was repeated by Wu and Co - workers 
(1986) in A549 cells infected with faecal samples from naturally infected 
humans.
As confirmation that c.p.e. in HAV - infected cells is due to HAV and not 
contaminating viruses Anderson et al, 1987 reported c.p.e. in BS-C-1 cells, 
which could be neutralized with HAV - specific monoclonal antibodies and 
convalescent sera from experimentally infected chimpanzees. In addition, the 
infective agent was shown to be extremely stable in conditions where only 
HAV would be expected to survive. The reason for the cytolytic nature of 
these strains remains unclear, but cellular factors and culture conditions (such 
as serum concentration and the age of the cells) are likely to be important. 
Several methods have been used to assay the infectivity of a vims sample. The 
first method of assay, immunofluorescence o f infected monolayers, has since 
proved to be too time consuming and was eventually replaced by simpler 
radioimmunoassays, techniques which have been refined for greater and 
greater sensitivity (Deinhardt et al, 1981; Siegletal, 1984; Vallbracht et al, 
1984; de Chastonay and Siegl, 1987). Lemon etal (1983) described a 
modification of the plaque assay which has become the standard infectivity 
assay for HAV. Cell monolayers are infected with serial dilutions of the test 
sample and covered with a media/agarose overlay as in a standard plaque assay.
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In order to visualize the plaques however, the monolayer is fixed and stained 
with HAV - specific polyclonal antibody followed by [,25I] - protein A. Though 
much simpler plaque assays are now also available for infectious HAV, the 
radioimmunofocus assay has the principle advantage of taking only 6 days to 
visualize plaques, whereas the plaque assay can take as long 14 days.
With the isolation of HAV in culture well established, several groups began to 
look at the kinetics o f HAV replication. Initially this was simply to look at the 
rate of antigen production, but eventually moved on to characterizing other 
aspects o f replication by recording the synthesis of virus - specific molecules 
(Locamini, 1981; 1982). In these studies, specific molecules were detected 
using the double - label co-electrophoresis and subtraction technique 
(Westaway, 1973), in which virus infected cells are labelled in vitro with [3H]- 
leucine whilst uninfected cells are labelled in vitro with [14C]-leucine. The two 
are then subjected to SDS-PAGE analysis, a labelled protein profile obtained 
by counting the gel slices and finally the uninfected profile subtracted from the 
infected profile to indicate virus specified proteins. Within 6 hours proteins 
and nucleic acids were detected with a similar size distribution to that of 
poliovirus - infected cells. This same macromolecular profile was also 
demonstrated from cells infected with HAV RNA, providing the first evidence 
that viral RNA is in fact infectious.
Unlike poliovirus however, recent studies using incorporation of radiolabelled 
amino acids into viral proteins (only recently possible with the advent of fast 
growing strains) suggest that there is a significant lag between virus protein 
production and their incorporation into virions. Improvements in infectivity 
assays have also allowed more detailed analysis of replication, with Wheeler 
et al.(1986a) making the important observation that HAV is not efficiently 
uncoated in tissue culture, with a substantial proportion of the inoculum being 
recovered for up to 12 hours, again in contrast to the behaviour of poliovirus.
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Though difficulties in detecting viral RNA have hindered studies o f replication, 
cDNA probes and the radioimmunofocus assay have established that it is the 
synthesis of RNA which is the rate limiting step in the replicative cycle of the 
cytopathic strain HM175 in BS-C-1 cells; with no apparent lag phase between 
synthesis of RNA and production of protein (Anderson etal, 1987). Anderson 
et al (1987) also confirmed the observation that HAV uncoats very slowly and 
that this is not due to slow penetration through the cell membrane. Preliminary 
studies have shown that the virus undergoes a series of changes before 
uncoating, with the virion becoming permeable to neutral red within 2 hr, 
although 160S virions can be recovered up to 8 hr after infection with no 
detectable RNA synthesis (Anderson et al, 1988). Studies also suggest that the 
restricted RNA production is as a result o f the high efficiency of RNA 
packaging within virions (Anderson et al, 1988). Another notable difference 
between poliovirus and HAV is that during poliovirus replication, progeny 
RNA is controlled such that there are large pools o f intermediates and 
polyribosomal RNA. In contrast, during HAV replication progeny RNA is 
continuously being packaged into virions. As a result the pool o f RNA 
available for replication is depleted (Anderson et al, 1988). Fig. 1.5 shows a 
model for the replicative cycle of HAV. Persistent infection in tissue culture is 
thought to be as a result o f a reduction in RNA synthesis (de Chastonay and 
Siegl, 1987), although a sub - genomic RNA species which may be associated 
with persistence has also been detected.
There is now a suggestion that defective interfering particles (DI) may play a 
part in persistence in cell culture (de Chastonay and Siegl, 1987; Garelick et 
al, 1988). These are HAV particles which have large deletions in the genome. 
They are not infectious but can inhibit infection by viable virions. DI particles 
have been identified in cell culture infected with various viruses and have been 
associated with persistence in Foot - and - Mouth disease infections in culture. 




multiplicities o f infection (m.o.i.), but as persistence in HAV has not been 
associated with high m.o.i. the significance of DI particles in HAV culture is 
unclear.
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1.2 VIRUS CELLULAR RECEPTORS
1.2.1 Introduction
The plasma membrane of cells represents, amongst other things, a barrier to 
invading organisms such as parasites and viruses. Even though it is impermeable 
to ions and small molecules as well as proteins and polypeptides, it is clear that 
viruses do transport their genomes and accessory proteins into the cytosol of the 
target cell.
A multitude of different methods have evolved for the transport of vital 
compounds and ions in and out of the cell and to facilitate communication with 
other cells. Since the plasma membrane has to be dynamic to do this, constantly 
cycling the molecules on its surface, it was considered likely that viruses would 
utilize these molecules to gain access to the cell. Though this point is now 
irrefutable, the details o f which molecules different viruses use, and how they 
use them are, in many cases, not understood. One thing is clear, the future of 
virus cellular receptor and cell biological research are likely to be closely linked. 
Research in this area has always been difficult. This is, in part, because of the 
problems associated with the techniques involved. Identification of the receptor is 
often hampered by weak affinities between virus and receptor, low receptor copy 
numbers on the cell surface, viruses utilizing more than one receptor type and the 
high degree of non - specific associations. The sensitivity of assays has also 
presented a problem, since a phase of replication prior to amplification of viral - 
associated molecules is often being measured.
Nevertheless with improvements in methods such as enzyme immunoassays and 
radiolabelling of virus, interest in the field continues. Indeed in some cases 
clinical applications of receptor identification and function are being utilized.
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1.2.2 Cellular Endocvtosis o f Viruses
Many viruses including alphaviruses, orthomyxoviruses, paramyxoviruses, 
rhabdoviruses, retroviruses, herpesviruses and a number of nonenveloped viruses 
use the endocytotic pathway to gain entry to target cells (Dales etal., 1973; 
Helenius et al., 1980; Matlin et al., 1982a,b). Morphological studies indicate 
that this usually occurs by receptor mediated endocytosis in clathrin-coated pits. 
Work with Semliki Forest Virus (SFV) suggests that the uptake of virus by this 
path is very similar to that used by physiological ligands. At 0°C virus is bound 
evenly over the surface of the cell. Upon wanning to 37°C viruses are relocated to 
coated pits and internalized in clathrin-coated vesicles. This sequence of events is 
not induced by the virus, is independent of multiplicity and can be blocked by 
anti-clathrin antibodies. Though the use of coated vesicles is common amongst 
viruses, some such as Sendai and Influenza, occasionally utilize non - coated 
vesicles resembling phagosomes as a portal of entry (Dourmashkin and Tyrell, 
1974; Matlin etal., 1982a).
Entry o f viruses into endosomes results in a vital sequence of events to enable 
successful infection of the cell. During normal function of endosomes, the acidity 
of the contents is gradually raised from about pH 6.2 in early endosomes, to 
around pH 5.0 in the late endosomes. This ensures the disassociation of 
physiological ligands from their receptors and, where appropriate, the down 
regulation o f receptors by degradation. This reduction in pH results in a change in 
capsid conformation, different viruses undergoing this change at different pH's . 
If, by the use of acidotropic weak bases such as amantadine, the pH is not 
allowed to fall, internalization does not occur. The use of endosomes also ensures 
that the virus is finally released into the cytosol in the perinuclear space where 
replication may begin.
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1.2.3 Entry of Enveloped and Non-Enveloped Viruses into the Cytosol
Many enveloped viruses fuse with the membrane during penetration of the target 
cell. This interaction takes place initially by way of a spike glycoprotein. In 
general these are oligomeric transmembrane molecules with a total molecular 
weight of between 200 - 400kDa, with the N - terminus on the external side of the 
membrane. It is this extracellular portion of the spike which represents the bulk of 
the glycoprotein, so-much-so that it is often visible under electron microscopy. 
Each virus particle contains 80 or more spikes, but it is unclear whether more than 
one at a time is required for infection. Many of these ’fusion factors’ have 
covalently bound palmitic acid and N - linked sugars. The N-linked sugars are 
implicated in the correct folding of the glycoprotein and its transport to the 
surface, whilst the role o f palmitylation is not clear. The fusion glycoproteins are 
subjected to proteolytic cleavage late in the secretory pathway, mediated by 
cellular proteases, which reveals hydrophobic N-termini, important for fusion in 
at least orthomyxoviruses, paramyxoviruses, coronaviruses and retroviruses 
(Choppin and Compans, 1975; Sturman et al., 1985; White et al., 1983). This 
proteolytic cleavage also occurs in SFV p62, but has been shown to be 
unnecessary for cell infection, whereas with Rhabdovirus G proteins there is no 
cleavage at all. Though there are obvious functional similarities between many 
fusion proteins, there is rarely any sequence homology, suggesting that the 
fusogens do not share a common ancestor.
One of the best characterized, and also one of the most effective fusogens is the 
haemagglutinin (HA) from the influenza virus, and as such represents an excellent 
model to describe entry of enveloped viruses into cells by membrane fusion.
The structure of the extracellular portion of HA has been determined by X-ray 
crystallography in its inactive neutral pH form (Wilson et al., 1981) and its 
synthesis has been described. It has been found to be a trimer (3 x 84kDa) in
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which each monomer consists of two polypeptides, HA1 and HA2. HA2 is 
primarily involved with fusion of the virus and cell membranes, whereas HA1 is 
involved in binding the virus to its cellular receptor, sialic acid. It is not essential 
for sialic acid residues to be present on the target cell surface for fusion, but it 
improves integration of the two membranes . The fusion of influenza membrane 
and its target cell membrane is pH dependent (Stegmann et al., 1988), requiring a 
drop in pH, and subsequent conformational changes in the HA trimer. As the pH 
drops, the most exposed domains of the HA1 molecules disassociate, revealing a 
hydrophobic face which is made up, in part, of the N-termini of the HA2 
molecules. Due to the hydrophobicity of the exposed face, the HA trimer is 
partially inserted into the target membrane and this in turn brings the two 
membranes into extremely close proximity. There is a resulting local dehydration 
between the opposing surfaces, and the two bilayers are able to flip and fuse, 
releasing the virus nucleocapsid into the cytosol.
There is still some doubt over the validity of this model however, particularly 
since there are known to be variations with other virus families. Some viruses 
require the presence of cholesterol in the membrane for effective infection (Kielian 
and Helenius, 1984), whereas others are pH independent and do not require an 
acid environment to fuse.
Fusion of virus and cellular membranes can occur at the cell surface without the 
use of endosomes if  the medium is acidified, but the virus may become trapped 
between the plasma membrane and the cytoskeleton and fail to infect the cell.
The method by which non-enveloped viruses gain entry to the cytosol, without 
fusion with the membrane, is far from clear but probably involves a 
conformational change in the virus capsid. In polioviruses the low pH 
environment of the endosome leads to the loss of the VP4 protein and viral RNA. 
It seems likely that with the extrusion of the myristylated (and consequently highly
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hydrophobic) VP4, the virus is aided in its translocation across the endocytic 
membrane. (Paul et al., 1987; Chow et al., 1987) The conformational change, 
which may be inhibited by weak bases, also reveals the amino terminus of VP1 
which helps to attach the virus to lipid vesicles (Hogle et al., 1988) and may also 
disrupt the pentamer-pentamer interaction of the virus capsid, opening a portal by 
which the virus RNA and VP4 may exit (Rossman et al., 1985). The 
myristylation status of VP4 in the Hepatitis A virus however, is still unresolved 
and this may have a bearing on the infectivity of the virus.
1.2.4 Viral Cellular Receptors
Whether a virus is enveloped or not, to infect a cell it is necessary for it to bind to 
a component of the cell surface to ensure that the virus is sufficiently close for 
internalization events to take place. The use of specific molecules on the surface 
of target cells also ensures that the virus associates with, and infects the correct 
cell type. In short the cellular receptor or viral attachment protein (VAP) for any 
particular virus also confers an initial cellular tropism upon it.
Viruses can bind to an array of cell membrane components, including proteins, 
glycoproteins, lipids, glycolipids and oligosaccharides. With the large range of 
possible cellular receptors available, (see Table 1.6) it is not surprising that a 
bank of different initial virus -cell interactions has appeared, which are largely 
dependent upon the receptor that is utilized.
Some virus groups have a high specificity for certain receptor molecules which are 
only present on a limited number o f cell types, such as HIV - 1 and 2, which 
utilize the CD4 molecule on the monocyte-macrophage cell lines, and the Epstein 
- Barr virus, which utilizes complement receptor 2. Though cellular tropism is not 
only determined at the receptor level, it is true to say that in many cases the 
possession of particular cell surface molecules can often determine cell type 
specificity.
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pi,3  GalNAc 




Human Adenovirus Class IHLA MHC 
molecule
(Chatteijee and Maizel, 
1984)
Residues 1-141 of E3gp 
(Chatteijeee and Maizel, 1984)
Herpesviridae 
Cytomegalovirus 
Human cytomegalovirus Residues 204-297 of H301 a  - 
domain gene product 
(Bech and Barrel, 1988)
Lymphocrytovirus 
Epstein-Barr virus C3d receptor CR2 
(CD21 o fB  
lymphocytes)
(Fingeroth et al., 1984)
Residues 21-29, 372-378,of 
gp350 (Nemerow et al., 1987). 
Residues 21-30,219-222, and 
372-460 of gp350 (Tanner et al., 
1987)
Residues 21-29 of gp350 
(Nemerow et al., 1989)
Poxviridae 
Orthopoxvirus 
Vaccinia virus Epidermal growth 
factor receptor 
(Eppstein et al, 1985)
Residues 71-80 o f VGF protein 
(Eppstein et al, 1985)
Hepadnaviridae 
Hepatitis B virus Hepatocyte receptor for 
polymerized serum 
albumin via albumin 
(Machida et al, 1984)
Hepatocyte receptor for 
polymeric IgA 
(Neurath et al, 1986)
Sialoglycoptroteins 
(Kom aietal, 1988)
PreS portion of Env protein 
(Machida et al, 1984)
Residues 21-47 of PreS 1 portion 
of Env protein 
(Neurath et al, 1986)
PreSl sequence of large protein 
(hepatocyte receptor) and preS2 
sequence of middle and large S 
proteins (polymerized serum 
albumin)
(Pontisso et al, 1989)
Table 1.6 Examples of virus cellular receptors (Lentz, T.L., 1990)
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Member o f the 
immunoglobulin 
superfamily 
(Mendelssohn et a l , 
1989)
Intercellular adhesion 
molecule - 1 (ICAM-1) 
(Greveetal., 1989; 
Staunton et al., 1989; 
Tomassini et al., 1989)
Sialoglycoproteins 






(Koike et al, 1991)
Residues 1-168 
(Domain 1 and 2) 
(Staunton et al, 1990)
Residues 95 - 105 of 
VP1 capsid protein 
(Murray etal, 1988)
Residues of VP1 and 
VP3 major capsid 
proteins lining a canyon 
on the virus surface 
(Rossmann et al., 1985) 
Lys-103, Pro-155, His- 
220, Ser-223, o fV P l 
protein. (Colonno et al., 
1988)
Residues of VP1 and 
VP3 major capsid 
proteins lining a pit on 
the virus surface 
(Luo etal., 1987)
Residues of 145-147 
(Arg, Gly, Asp) and 
203-213 of VP1 protein 
(Fox etal., 1989) 
Residues 133-158 and 
C-terminal region of 
VP1 protein 
(Acharya et al., 1989)
Reoviridae 
Reovirus 
Reovirus 3 P-adrenergic receptor 
(Co etal., 1985) 
Sialoglycoproteins 
(Paul and Lee, 1987)
C-terminal portion of 
haemagglutinin 





Lactate dehydrogenase - 
elevating virus
Class IHLA and H-2 
MHC molecules 
(Helenius et al., 1978)
Class II la  MHC 
molecule of 
macrophages 
(Inada and Mims, 1984)
Table 1.6 Continued
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Influenza virus Sialyloligosaccharide 






(Paulson et al., 1979; 
Carroll et al., 1981; 




Residue 226 of 
haemagglutinin (HA) 
(Rogers et al., 1983)
Ty r-98,T rp-15 3 ,His- 
183,Glu-190,Leu-194, and 
neighbouring pocket 
residues of HA 










Sendai virus Sialyloligosaccharides 
(Paulson et al., 1979)
NeuAca2,3Galp 1,3GalNAc 
(Paulson et al., 1979) 
NeuAca2,8NeuAca2,3 Gaip 
l,3GalNAc 




(Paulson et al., 1979)
NeuAca2,3Gaip l,3GalNAc 






(Schlegel et al., 1983; 
Mastromarino et al., 
1987) 
Phosphatidylinositol 
(Mastromarino et al., 
1987)
GM3 ganglioside 
(Mastromarino et al., 
1987)
Lyssavirus 
Rabies virus Acetylcholine receptor 
(Lentz etal., 1982) 
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Alternatively, a number of viruses bind, with considerable specificity, to cell 
surface molecules which are common to many cell types. Such viruses include 
orthomyxoviruses and paramyxoviruses, which bind sialic acid. Sialic acid is 
present on all mammalian cells, with the only variations being in the linkages 
between the sialic acid residues and adjacent sugars. As well as occurring on most 
mammalian cell types, sialic acid is often also the terminal sugar on 
oligosaccharides of glycoproteins and glycolipids, and consequently myxoviruses 
can bind to a wide variety of cells. Sialic acid has also been implicated in the 
binding of picomaviruses, papovaviruses, reoviruses and adenoviruses (Bumess 
et al., 1981). Complex carbohydrate moities have also been associated with the 
binding of many other viruses (e.g. herpes simplex virus, which utilizes heparan 
sulphate as the initial cellular binding site).
Viruses that use common cell surface molecules as binding receptors, and as a 
result display a broad binding tropism, do not necessarily replicate in those cells 
but instead require intracellular determinants of replicative tropism.
Certain virus groups, such as Alphavirus, rhabdovirus, and vesicular somatitis 
vims (VSV) also appear to have a broad binding host range but have a far lower 
affinity for their receptors, and in some cases a far lower specificity. SFV, like 
several other viruses, appears to use more than one type of receptor molecule as a 
method of entry into cells. It is known to bind to the major histocompatability 
complex (MHC) class I on lymphoblastoid cells (Helenius et al., 1978), but is 
also known to bind to cells that do not bear these proteins (Oldstone et al., 1980). 
Several vims groups may share the same cellular receptor, as has been 
demonstrated by competition binding assays. On HeLa cells for example, four 
distinct binding sites are used by a number of non-enveloped viruses. Group 1 by 
HRV 2, 1A and IB; group 2 by coxsackievirus type A21 and HRV types 3, 5,
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14, 15, 39, 41, 51; group 3 by all 3 serotypes of poliovirus and group 4 by 
coxsackievirus B3, other coxsackieviruses and adenoviruses 2 and 5.
Two other common mechanisms have also been described for initial virus cell 
interaction; the use of coat proteins from other viruses, expressed on the surface 
of an infected cell as a cellular receptor, and the binding of virus to cells via an 
intermediary molecule.
In the first situation, a cell may be infected with a virus, such as influenza which 
expresses its HA on the cell surface. Since HA binds specifically and with great 
affinity to sialic acid, any virus bearing sialic acid as part of a glycoprotein on its 
surface (e.g. the envelope G protein of VSV) is able to utilize the influenza HA as 
a receptor to subsequently infect the cell (Fuller et al., 1985). Though this effect 
has only been shown in vitro, these 'secondary infections' may also occur in vivo. 
Use of an intermediary molecule, as opposed to direct interaction of virus with 
cell, is not uncommon, with some of the best examples occuring via antibody 
molecules. Antiviral antibodies enhance the binding of flaviviruses, myxoviruses 
and lentiviruses, where antibody cross-links the virus and the cell via the cells Fc 
receptors (McGuire et al., 1986; Peiris and Porterfield, 1979; Peiris et al.,
1981; Webster and Askonas, 1980) Hepatitis B virus is believed to bind to 
hepatocytes via polyalbumin and polymeric albumin receptors (Thung and Gerber, 
1984). The continued role o f the cellular receptor after binding and endocytosis 
varies from virus to virus. The receptors for influenza virus, alphavirus and 
rhabdovirus are not required for fusion to target cell membranes, whereas the 
receptor for poliovirus may be needed to ensure the correct conformational 
changes in the virus in order to facilitate entry into the cell from the endosome.
The ability of a cell membrane molecule to act as a receptor for a virus is not 
simply determined by whether the sequence for that protein is encoded in the 
target cell genome. For instance, RNA coding for the poliovirus receptor has
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been detected in many different cell types, even though the virus is known not to 
infect these cells. It is possible that cell specific post-translational modifications 
are required for the protein to be expressed on the cell membrane, or that the 
presence of additional proteins is needed for successful virus binding and 
internalization. Equally, Influenza virus utilizes sialic acid as a cell binding site, 
but does not infect all cells bearing that moiety, even if  the virus subsequently 
enters the cell by endocytosis and membrane fusion.
In these cases it is necessary for a more complex cell membrane mechanisms (as 
seen with herpes simplex virus) or an intracellular mechanism such as cellular 
polymerase specificity to determine cellular tropism.
1.2.5 Clinical Implications of Virus - Cellular Receptor Interaction 
One important feature of a the interaction between a virus and its cellular receptor 
is that in order to maintain the ability to bind to a particular cell type, the virus 
cannot mutate its cell binding site to any degree. As a consequence, either the 
cell binding site on the virus, or the cellular receptor on the target cell can be used 
as a target for anti-viral therapy, with little or no danger of major changes to their 
structure. This is of particular relevance in the case o f viruses such as HIV and 
Influenza, which evade the host's immune response by frequently altering their 
envelope glycoproteins. Some viruses have evolved "canyons" on their surfaces, 
at the bottom of which lies the cell binding site. The canyon is of such a 
conformation that antibodies to this area are unable to bind to the cellular binding 
site. This type of capsid conformation has been described in Rhinovirus 
(Rossmann et al., 1985), Mengo virus ( Luo et al., 1987) and on the 
haemagglutination glycoprotein of the Influenza virus (Weis et al., 1988), where 
a three-dimensional structure of HA complexed with sialyllactose shows the acid 
filling the pocket. The role o f antibodies directed to the rims of these canyons, 
and subsequent steric interference with binding, has yet to be determined for
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many viruses. In the case o f Influenza virus it has been shown that neutralizing 
monomeric IgG and IgA do not inhibit binding, whereas larger polymeric IgA 
and IgM do reduce binding (Taylor and Dimmock, 1985a, b). The neutralization 
site for Rhinovirus 14 is located on protrusions from the virus surface (Sherry et 
al., 1986) as is the neutralization site for Foot-and Mouth-Disease-Virus (FMDV) 
which does not possess a canyon at all (Acharya et al., 1989). In this instance the 
cell binding motif of arginine - glycine - aspartic acid is situated in a hypervariable 
immunodominant region (Fox et al., 1989) which may suggest that a cellular 
binding site on the virus may evade antibody neutralization by being too small 
(Colman et al., 1983; Harrison, 1989)
Since viruses often utilize cell membrane bound molecules which have a normal 
physiological function, it is not surprising that the sequence of cell binding 
proteins on viruses often show homology with natural ligands (see table 1.7). As a 
result, binding of viruses can affect the target cell physiologically, or even subvert 
the immune response to it by causing autoimmune disease to tissues carrying that 
particular characteristic (Oldstone, 1987). All of these events are generally 
termed molecular mimicry. (Damian, 1987). The physiological effects o f a virus 
binding to one of its receptors may, in some cases, be so drastic that they 
manifest themselves as symptoms of the disease, particularly if  the virus sheds an 
excess of its binding protein. The vaccinia virus encoded VGF protein, for 
example has been shown to stimulate tyrosine kinase, as a result o f its similarity 
to epidermal growth factor (King et al., 1986); and the receptor-mediated 
leukaemogenesis hypothesis proposes that murine leukaemia viruses induce 
lymphocyte proliferation by binding to antigen - specific receptors complementary 
to virus envelope gene products (McGrath et al., 1987). The psychological 
symptoms experienced by rabies victims may be accounted for by the rabies virus
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Adenovirus glycoprotein (102-116) 
Immunoglobulin M k  chain, human (83-97)
DITMYMSKQYKLWPP 
DIATYY COOYNN WPP
Epstein-Barr Virus gp350 (372-378)(21-29) TPSGCEN EDPG-FFNVE
Complement C3d fragment (1006-1012)(1221-1231) TPSGCGE EDPGKOLYNVE
Human Cytomegalovirus H301 gene product (261-286) DGTFHQ--GC YV-Al F CNQN YTCRVTH
Class I MHC molecule a-3 domain, human 
(consensus)
DGTFOKWAAVW-PSG-EORYTCHVOH
HIV-1 gpl20 (193-200) ASTTTNYT
Vasoactive Intestinal polypeptide (4-11) AVFTDNYT
HIV-1 gpl20 (61-88) CASDAKAYDTEVHKVWATHACVPTDPNP
Immunoglobulin y heavy chain, human (84-111) CNVDHKPSNTKVDKTVERKCCVECPPCP
HIV-1 gpl20 (245-273) VQCTHGIRPWSTQLLLNGSLAEEEWIR
Neuroleukin (410-438) VOTOHPIRKGLHHKILLANFLAOTEALMR
HTLV-1 gp (246-253) SVPSSSST
Interleukin 2, human (20-27) SAPTSSST
Rabies virus gp (189-199) CDIFTNSRGKR
Naja naja naja (India) toxin b (30-40) CDGFCSSRGKR
Vaccinia virus VGF protein (69-80) CRCSHGYTGIRC
Epidermal growth factor, human (31-42) CNCWGYIGERC
Table 1.7 Examples of similarities between virus attachment proteins (VAP) 
and their mimics. ( reproduced form Lentz, T.L. 1990)
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glycoproteins, which can compete for binding to acetylcholine receptors 
(Donnelly - Roberts and Lentz, 1989).
There are theoretically two groups of compounds which should be able to block 
virus binding to its target cell; the first are natural or synthetic molecules which 
mimick the cell binding site of the virus. The other group are compounds which 
mimick the cellular binding site on the ceil surface. Examples of both of these 
groups have been shown to be effective.
(i) Agents Mimicking the Virus's Attachment Protein ('YAP mimics’)
Antibodies to the CD4 molecule of the HIV virus target cell can be inhibitory to 
virus binding (Landau et al., 1988; Mizukami et al., 1988), as can antibodies 
raised against monoclonal antibodies to the HA of reovirus (anti idiotypic 
antibodies) (Kauffman et al., 1983). These antibodies have particular importance 
since they can elicit an immune response to a virus without exposure to the virus 
itself. Natural ligands, physiological or not, can inhibit binding of a virus; such 
as a-Bungarotoxin for Rabies virus (Lentz et al., 1982) or epidermal growth 
factor in the case of Vaccinia virus (Eppstein etal., 1985). However, these types 
of compounds have little therapeutic use since they also exert toxic effects. The 
last type of compound able to mimic virus attachment protein are synthetic 
peptides based on known sequences.
(ii) Agents Mimicking the Cellular Binding Site
Essentially, these compounds mirror the actions of the 'VAP mimics'. As has 
been described in section 1.2, antibodies to the coat protein of the virus will 
compete with the cellular binding site and may, in some cases, neutralize the 
virus. These antibodies can be raised to whole virions, purified virus structural 
proteins, or synthetic peptides known to represent immunogenic regions of the 
virus. These methods have been used successfully with numerous viruses, 
including hepatitis B vims ( Itoh et al., 1986), the VP 1 protein of FMDV
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(DiMarchi et al., 1986), HIV gpl20 (Lasky et al., 1987; Dowbenko et al.,
1988; Sun et al., 1989) and human rhinovirus (McCray and Werner, 1987). Such 
neutralizing antibodies do not necessarily have to be directed to the binding site 
itself, but to a site sufficiently close to inhibit binding by steric hindrance. Anti- 
idiotypic antibodies against an anti-CD4antibody mimic the CD4 molecule and 
bind the HIV glycoprotein, partially neutralizing the virus. Again, synthetic 
chemicals can be assembled which contain the virus binding site, as with 
Influenza virus where compounds such as NeuAcaCH2, NeuAcaC7H7 as well as 
sialyloligosaccharides containing NeuAca2,6GlcNAc or NeuAca2,6Gal 
(depending on the strain used) inhibit virus adsorption to erythrocyte membranes 
(Pritchett et al, 1987)
1.2.6 Methods of Characterization and Purification of Virus Cellular Receptors 
(T) Anti-Receptor Monoclonal Antibodies
One of the most popular methods for the purification of virus cellular receptors is 
the raising of a monoclonal antibody to it, and to use this to purify the receptor, 
by some form of immunoaffinity chromatography. This type of monoclonal 
antibody can be isolated by screening for its ability to block infection, since in 
many cases (but not all, see Herpes Simplex Virus) the only molecule relevant to 
virus infection, on the surface of a permissive cell, is the cellular receptor. 
Generally, mice are immunized with whole cells, as they are more antigenic than 
sub - cellular fractions. Having established that the animal is producing antibodies 
capable of blocking infection (by pretreating a cell monolayer with a tail vein 
bleed prior to infection, and subsequently identifying plaque reduction) the spleen 
cells can be immortalized by fusion with mouse myeloma cells, using methods 
which have been described previously (Kohler and Milstein, 1975). The resulting 
hybridomas can be tested to find a monoclone which will inhibit infection, as has
43
been successfully accomplished with the major group Rhinoviruses (Colonno et 
al., 1986).
If this highly labour - intensive task is successful, then the relevance of the 
monoclone can be confirmed by inhibiting the binding of radiolabelled virus to a 
permissive cell line, as opposed to simply inhibiting infection. If this too proves 
successful, the monoclonal antibody can then be used to immunoaffinity purify 
the receptor for detailed structural analysis, such as glycosylation status and N - 
terminal sequencing.
Having isolated an anti-receptor monoclonal antibody, it is also useful to test for 
its ability to block the binding of other viruses, since the sharing of receptors is 
known to occur. Such a comparison has been performed with the anti - receptor 
antibody for the major group rhinoviruses, where it was discovered that the same 
antibody also inhibited the binding of Coxsackievirus A21, though it did not 
inhibit the binding of other Coxsackieviruses or Poliovirus.
Molecular Cloning
It has been established that suceptibility to infection by a virus can be conferred 
upon a cell line by transforming that cell line with DNA from permissive cells. 
This was most notably achieved by Mendelssohn et al.(1986) with the 
transformation o f non-permissive L-cells with human DNA. Mendelssohn et al., 
(1989) subsequently used these techniques to clone the poliovirus cellular 
receptor directly. The group repeated the earlier work, by transforming mouse L 
cells with DNA from HeLa cells to create CM-1 cells, and testing for poliovirus 
antigen production by standard plaque assay. In order to isolate the virus cellular 
receptor, L cells were transformed with DNA from the CM-1 cells, and the 
presence of human sequences containing the receptor established by plaque assay, 
restriction digests and the use of a DNA probe for Alu repeats (a characteristically 
human sequence). As a result, it was established that the poliovirus receptor has
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an Alu repeat associated with it in a lOkb fragment. A genomic library was 
constructed from one secondary transformant containing this fragment and was 
screened for Alu repeat sequences. Three bacteriophage recombinants were thus 
isolated. One recombinant contained mouse sequences and the other two contained 
a lkb BamHl fragment, which was present in all secondary transformants, and 
hybridized with DNA from HeLa cells and SY5Y neuroblastoma cells (both 
permissive) but not L cells (not permissive). This 1 kb fragment was then used to 
probe HeLa cell cDNA libraries for the whole receptor. By this method, an open 
reading frame was cloned, which when transfected into non - permissive cells, 
rendered them liable to infection with poliovirus.
Virus Overlay Protein Blot Assay (VOPBA)
This approach was used for the estimation of the molecular weight of the putative 
cellular receptors for Visna Virus (Crane et al., 1991; Dalziel et al., 1991), 
Human Cytomegalovirus (Adlish et al., 1990) and Lymphocytic Choriomenigitis 
Virus (Borrow and Oldstone, 1991).
Essentially, whole cells or membrane preparations from cells known to be 
permissive for the virus under study, are subjected to SDS - PAGE and western 
blotted onto nitrocellulose. The blot is then incubated with labelled virus and the 
position where the virus has bound is visualized by an apppropriate method. 
Alternatively, the virus may be indirectly detected by a labelled, virus - specific 
polyclonal or monoclonal antibody. The molecular weight of the virus - binding 
sites on the cell surface can then be calculated. This method can be extended to 
investigate which cell lines the virus may bind to, which viruses may share the 
same binding sites, and what agents inhibit virus binding. The main problem with 
this method is that the virus binding site, in many cases, will be disrupted during 




Anti-idiotypic antibodies are antibodies raised to the portion of a monoclonal 
antibody raised to regions of the virus surface. As such, it is possible that they 
may be able to mimic the cell binding sites on the virus surface, and therefore 
may be used as a probe for, and subsequently immunoprecipitate, the virus’s 
cellular receptor. In the case of Sindbis Virus (Wang, K.-S. et al., 1991) it was 
found that such an antibody could partially inhibit virus infection of chicken cells, 
but would not inhibit the infection of BHK cells, suggesting that Sindbis Virus is 
able to utilize more than one type of cell surface protein as a means of entry. 
Although a bank of anti - virus monoclonal antibodies can be used as 
immunogens, it is clearly easier to make use of this technique if an antibody is 
known to neutralize through the virus's cell binding protein.
Interference with Virus Binding
It has also been possible to discover the nature of the cellular receptor either by 
incubating the virus with compounds which mimic the cellular receptor, or by 
treating the surface of the target cell with various enzymes.
The best example of this is the inhibition of influenza virus - induced 
haemagglutination, by first treating the red blood cell surface with neuraminidase 
to remove the sialic acid residue of oligosaccharides.
This proved that sialic acid can play an important part in virus binding and entry 
into the cell. Use of neuraminidase has been extended to other viruses such as 
bovine coronavirus, encephalomyocarditis virus and picomaviruses.
The binding site of Herpes Simplex Virus has been shown to involve cell surface 
heparan sulphate, by interfering with infection using heparin or enzymes which 
very specifically destroy heparin sulphate, such as heparinase and heparitinase 
(WuDunn and Spear, 1989).
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Copurification of Virus and its Cellular Receptor
It is possible to use the virus itself as an affinity ligand in an attempt to purify the 
cell surface receptor. Mapoles et al. (1985) isolated a tightly bound virus - 
receptor complex by incubating Coxsackievirus B3 with HeLa cells, and then 
solubilizing the cells with sodium deoxycholate and Triton X-100. The VRC was 
then purified 30,000 fold by differential and sucrose gradient ultracentrifugation. 
Iodination of the VRC, and SDS-PAGE analysis allowed the group to estimate the 
molecular weight o f the binding protein. This approach is the only direct method 
of purifying the whole receptor in one step, and provided yields are good, allows 
a very effected way o f gaining detailed information about the receptor.
1.3 AIMS OF THE PROJECT
At the commencement of the project, the information available regarding the 
distribution and structure of the cellular receptor for hepatitis A virus was 
extremely limited, relying mainly on clinical data and comparisons with other 
picomaviruses.
In particular, one important question remained unanswered; does hepatitis A infect 
gut (and other) cells in order to finally infect (and reinfect) the liver? (see Fig. 1.8) 
It was known that poliovirus can infect gut cells during its passage from the gut to 
the neuronal cells, so it was suggested that this must be the case for hepatitis A, 
though evidence had yet to be obtained. One way of answering this question 
would be to establish a method of screening certain cell types for their ability to 
support virus replication. This has been achieved for other viruses by confirming 
the presence or absence of certain cell surface molecules which act as their cell 
binding sites.
Therefore, the first aim of the project was to investigate the possibility of raising 









Fig. 1.8 Pathological mechanism of hepatitis A.
virus. This was likely to be an extremely time consuming undertaking, since it 
would be impossible to screen initially for inhibition of infection (typical HAV 
replication times in cell culture are between 7 and 14 days). As a result, the only 
option was to develop a cell binding assay and to use this in a cell protection 
assay (HAV versus monoclonal antibody competition binding assay).
In keeping with the general approach to monoclonal antibody isolation, some 
attempt would also be made to purify or partially purify the cellular receptor by 
co-isolating it with purified HAV. Two approaches could be investigated; a 
virus- receptor complex could be purified by the same method as for standard virus 
purification, or the cellular receptor could be localized on SDS-PAGE by virus - 
overlay protein blot assay. Both preparations could then be used as immunogens 
for antibody production. These two methods would also yield information as to 
the molecular weight of the receptor and indirectly, its composition.
At the time, the inhibition of virus binding by a polyclonal antibody to the 
surface of FRhK-4 cells had been shown, by other workers, to be unattainable 
(Anderson, D.A. personnal communication) and so other methods would be used 
to gather general information about the receptor and its distribution.
Though not strictly applicable to the clinical situation, a study of virus binding to 
a range of cells was considered relevant, to try to establish discrete binding 
between permissive and non-permissive cells. It was intended that this would be 
extended to look at some features of the kinetics of virus-cell interaction and also 
the number of receptor copies per cell. The binding assay would also be used to 
investigate which treatments of the cell surface would repress binding. This 
information could then be interpreted to gain some basic information about the 
composition of the receptor.
The neutralization of HAV by monoclonal and polyclonal antibodies was also an 
area which lacked information. The most relevant piece of information was the
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observation that there is only one wild type serotype of HAV known. Therefore it 
was proposed that to escape neutralization by polyclonal antibody may well prove 
fatal to the virus. Three HAV - specific monoclonal antibodies were available, 
two shown to neutralize HAV and one not. These monoclonal antibodies would 
be used to investigate the possibility that the portion of the virus capsid which 
binds to the cellular receptor may also represent an epitope for neutralizing 
antibodies.
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2. MATERIALS AND METHODS
Unless otherwise stated all tissue culture disposables, media and supplements 
were obtained from Gibco, Flow and Sterilin and all reagents were analytical 
grade obtained from Sigma or BDH.
2.1 CELLS
Foetal Rhesus monkey kidney cells (FRhK-4) were provided by Dr. B.
Flehmig, Hygiene - Institute, Department of Medical Virology, Tubingen, 
Germany and grown at 37°C in Dulbecco's modification of Eagles medium. 
Chinese hamster ovary cells (CHO) were grown at 37°C in Ham's F12 medium 
and WRC were grown at 37°C in 199 medium. All media were supplemented 
with 2mM glutamine, 10% foetal calf serum (FCS), lOOpg/ml streptomycin and 
lOOU/ml penicillin. Cells were split weekly after treatment with 0.5% trypsin 
and maintained in 75 cm^ flasks.
2.2 VIRUS
The HM175 strain of HAV was originally recovered from the faeces of a 
naturally infected human in Australia. It was provided by Dr. John Wood, 
National Institute of Biological Standards and Controls, Potters Bar, Herts 
having been passaged 6 times in marmoset livers, 10 times in AGMK cells and 
twice in BS-C-1 cells. (Daemer et al, 1981; Coronas et al, 1989) To produce 
HAV HM175 seed, a confluent monolayer of FRhK-4 cells was inoculated 
with 800 pfu/ml of cell associated virus seed in PBS for 90 min. at 35°C. The 
inoculum was then removed and replaced with DMEM maintenance medium 
(DMEM supplemented with 1% FCS, 2mM glutamine, 100 jag/ml 
streptomycin, lOOU/ml penicillin ) for 10 days at 35°C after which the medium 
was removed and clarified by centrifugation at 15.000g for 20 min. and stored 
at -70°C until required (supernatant (s/n) virus stock). The infected monolayer
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was lysed by three cycles of freeze / thawing in dry ice and clarified by 
centrifugation at 15,000g for 20 min. and then stored at -70°C until required 
(cell associated (c/a) virus stock 8 x 104 pfu/ml). Cell associated virus stocks 
were used in subsequent passaging of the virus at a multiplicity of infection 
(m.o.i.) o f  4 x  10-4.
2.3 SERA AND ANTIBODIES
Pooled IgG fractions of human convalescent sera was provided by Dr. Hemda 
Garelick, London School o f Hygiene and Tropical Medicine, London, WC1. 
Pooled convalescent sera was provided by Dr. Diane Westmoreland, Public 
Health Laboratory Service, Bath, Avon. An HAV specific, non - neutralizing 
mouse monoclonal antibody, 14H / LSHTM was provided by Dr. Hemda 
Garelick, London School of Hygiene and Tropical Medicine, London, WC1. 
Two HAV specific neutralizing mouse IgG monoclonal antibodies, 813 and
10.09 were provided by Clonatec - Biosoft department, 60, rue de Wattignes, 
75580, Paris cedex 12.( Crevat et al, 1990; Ping and Lemon 1992)
2.4 PROTEIN ESTIMATION
A series o f bovine serum albumen protein concentration standards were made 
up in PBS from a stock solution of 0.5 mg/ml to give final concentrations of 2, 
4, 10, 20 and 40 pg/ml in lOOpl in microtitre plate wells.
The working detection solution was made up as follows. Three solutions were 
made up, each of which are stable at room temperature. Microreagent A (MA) 
(4g sodium carbonate monohydrate, 0.8 g sodium hydroxide, 0.8 g sodium 
tartrate in 50 ml ddH20 [ pH 11.25, with sodium tartrate]; microreagent B (2 
g bicinchoic acid (Pierce) in 50 ml double distilled H2O (ddH2 0 )) and 
microreagent C (40pl 4% copper (II) sulphate and 960 pi MB). The final 
working solution was 1 volume of MA added to 1 volume MC which was 
prepared on the day of use. lOOpl of the working solution was added to the
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protein standards and to the appropriate dilutions in lOOpl of the protein test 
samples and incubated at 60°C for 1 hr. The result was then be read on a 
microtitre plate reader at 562nm.
2.5 SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL 
ELECTROPHORESIS.
Electrophoresis in the presence of SDS was performed using a method based 
upon that of Laemmli (1970).
A 12.5% polyacrylamide slab gel was poured and overlaid with water saturated 
butanol. Once it had set the water/butanol was removed and a 4% 
polyacrylamide stacking gel poured on top, wells were formed by placing a 
comb in the top. 0.248M Tris - HC1 [pH 8.7] and 0.345M Tris - HC1 [pH 6.8] 
buffers were used for the resolving and stacking gel respectively. In both cases 
polymerization was achieved by the use of ammonium persulphate and 
N,N,N',N - tetramethylethylenediamine (TEMED).
The protein samples were mixed with sample buffer ( 12.5% v/v 0.5M Tris - 
HC1 [pH 6.8], 20% v/v glycerol, 2% w/v SDS, 5% v/v P - mercaptoethanol 
and 0.0025% w/v bromophenol blue ) and boiled for 5 min prior to loading. 
Molecular weight markers ( Pharmacia LKB) were made up according to 
manufacturers instructions and also boiled prior to loading. The gel was run at 
2 0 - 3 0  mA (30 mins.) for the stacking gel and increased to 40-50mA following 
the interface with the resolving gel (4hrs).
2.6 COOMASSIE STAIN OF POLYACRYLAMIDE GELS
Following electrophoresis the gel was stained for 1 hr at room temperature in 
coomassie blue stain ( 0.25% w/v coomassie blue stain in fixing solution ( 30% 
methanol, 10% acetic acid, 60% ddH2 0 )) and then destained in several 
changes of fix until the background colour was removed.
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2.7 SILVER STAIN OF POLYACRYLAMIDE GELS.
Following polyacrylamide gel electrophoresis, the gel was prefixed in a 50% 
methanol, 10% acetic acid solution for 30 min and then a 5% methanol, 7% 
acetic acid solution, also for 30 min. Without rinsing the gel was then fixed 
for 30 min in 10% gluteraldehyde and washed in a large volume of ddF^O 
overnight followed by a quick wash in ddH^O the next day. Following a 30 
min soak in 5pg/ml dithiothreitol the gel was immersed in a 0.1% solution of 
silver nitrate for 120 min. The gel was then briefly washed once in ddF^O and 
twice in developer ( 50pl 37% formaldehyde in 100 ml 3% sodium carbonate). 
The protein bands were visualized by bathing the gel in developer until the 
desired level o f staining had been attained. Staining was stopped by adding 5 
ml 2.3M citric acid to the developer and shaking for 10 min. The gel was 
washed three times in ddH^O and once in 0.03% sodium carbonate before 
being sealed in a plastic bag.
2.8 PROTEIN RADIO - IODINATIONS.
lOpg of protein solution in 25 pi 0.5 M sodium phosphate [pH 7.5] (0.5M 
Na2HPC>4 adjusted to the correct pH with 0.5 M NaH2PC>4) was added to 0.5 
mCi Na125I in a 3ml stoppered plastic test tube and stirred with a small magnetic 
flea. The iodination reaction was started by the addition of 25pi 0.2 mg/ml 
chloramine T in sodium phosphate buffer and allowed to proceed for exactly 60 
sec at room temperature with stirring. The reaction was terminated with the 
addition of stop buffer ( 0.24 mg/ml sodium metabisulphite, 10 mg/ml 
tyrosine, 10% glycerol and 0.1% xylene cyanol in PBS ). The iodinated 
protein was separated from the 125Iodotyrosine on an appropriate size exclusion 
column, in this case a 10 ml Sephadex G50 ( Pharmacia LKB) swelled and 
blocked in 1% BSA in PBS followed by equilibration in 0.5M sodium 
phosphate. 0.5 ml fractions were collected and the position of the iodinated
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protein established on an LKB gamma counter. All manipulations involving 
Na125I took place in an approved fume hood.( Greenwood and Hunter, 1963)
2.9 QUANTITATION OF HAV - SPECIFIC ANTIBODIES BY DIRECT 
ENZYME-LINKED IMMUNOSORBENT ASSAY.
Three strips o f eight microtitre plate wells w ere coated with a 1/1000 dilution 
of monoclonal antibody ( m Ab) 813 (0.6pg/ml), a 1/1000 dilution of mAb
10.09 (unknown concentration) and a 1/1000 dilution of mAb LSHTM/14H 
(unknown concentration) respectively, in bicarbonate buffer (0.16 %
Na2CC>3, 0.30% NaHCC>3, [pH9.6]) for 2 hr at 37°C, followed by an 
incubation for 2 hr at 37°C in blocking buffer (0.3% Tween 20, 1% dried milk 
powder in PBS) to occupy any vacant non - specific binding sites on the 
plastic. Doubling dilutions of the detecting, horse - radish peroxidase 
(HRPO) conjugated sheep anti - mouse IgG antibody (Amersham International, 
Amersham, Bucks, UK.) between 1/100 and 1/12800 were prepared in 
blocking buffer and added to each well such that each monoclonal antibody 
was exposed to each dilution of detecting, conjugated, monoclonal antibody. 
The wells were incubated with the detecting antibody for 2 hr at 37°C. The 
result was visualized with 100 pi 1% tetraaminobenzidine ( in DMSO ) in 10 
ml of a 1/20 dilution of a citrate/acetate stock buffer (68 g sodium acetate, 3.15 
g sodium citrate in 500 ml ddH2 0  [pH 6.0]) containing 2pi H2O2. The 
reaction was stopped by the addition of 50pl 1.84M H2SO4 and the results 
read at 450 nm in a microtitre plate reader.
The results were obtained by the construction of a standard curve using values 
obtained for the known antibody concentration (813, 0.6mg.ml) (fig.2.1).
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Fig. 2.1 Standard curve of [IgG] against absorbance for direct ELISA 
quantitation of anti - HAV monoclonal antibodies.
2.10 COMPETITION RADIOIMMUNOASSAY BETWEEN HAY-SPECIFIC
ANTIBODIES
Microtitre plate wells were coated with a 1/1000 dilution of mAb 10.09 (0.22p 
g/ml) in carbonate coating buffer for 2 hr at 37°C, and blocked for 2 hr at 37° 
C in blocking buffer. A saturating dilution of HAV was then added to the 
wells, again in blocking buffer, and incubated at 37°C for 2 hr, followed by 
an incubation at 37°C for 2 hr with each competing monoclonal antibody, 
10.09, 813 and LSHTM/14H at 0.22 pg/ml. The wells were then incubated 
with 1 x 10  ^cpm of [125I] - mAb 10.09 for 2 hr at 37°C in blocking buffer. The 
wells were washed three times in blocking buffer between each incubation. To 
establish competition binding between the three monoclonal antibodies, the 
wells were cut away from each other, placed in LP4 tubes and counted on an 
LKB gamma counter.
2.11 HAV DETECTION BY SANDWICH. ENZYME-LINKED 
IMMUNOSORBENT ASSAY.
HAV specific mouse monoclonal antibody LSHTM/14H was diluted in 
bicarbonate buffer and used to coat polystyrene wells (0.33pg/ml) overnight at 
room temperature, and then blocked in blocking buffer for 2 hr at 37°C. Test 
samples of HAV in blocking buffer were loaded into the wells and incubated at 
37°C for 2hr. An IgG fraction of pooled convalescent sera (0.88 pg/ml) was 
added to each well and incubated for 2 hr at 37°C, followed by a 1/1000 
dilution of mouse anti-human monoclonal antibody, conjugated to alkaline 
phosphatase also at 37°C for 2hr in blocking buffer. Three washes in blocking 
buffer took place between each incubation. To develop the assay lOOjil of 
carbonate buffer (0.16% Na2CC>3, 0.30% NaHCC>3, [pH9.6]) containing 1.6 
mg/ml p-nitrophenyl phosphate was added to each well. When the colour had
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developed sufficiently, the absorbance was measured on a microtitre plate 
reader at 405nm.
2.12 AMMONIUM SULPHATE PRECIPITATION OF IgG.
FRhK - 4 specific mouse polyclonal serum was centrifuged at 3000g for 30 
min to remove any large aggregates and sealed in activated dialysis tubing.
The serum was dialysed overnight at 4°C against a large volume of 30% 
ammonium sulphate [pH 7.4] to slowly precipitate large protein aggregates 
which were then removed by centrifugation at 3000g for 30 min. The serum, 
in 30% ammonium sulphate was dialysed overnight at 4°C against a large 
volume of 50% ammonium sulphate to precipitate only the IgG fraction of the 
mouse serum. IgG was recovered in 0.5 volumes of PBS and dialysed against a 
large volume of PBS to remove any remaining ammonium sulphate. The 
resulting solution was centrifuged once more to remove debris, tested for 
purity on SDS - PAGE and stored at -70°C in 50% glycerol.
2.13 HAV PLAQUE ASSAY
Confluent monolayers of FRhK- 4 cells were prepared in 10 x 60mm petri 
dishes. The cells were infected with serial dilutions of an HAV sample 
between 10"2 and 10“8 in PBS at 35°C for 90 min. The inocula were removed 
and the cells overlaid with DMEM maintenance medium containing 0.5% 
Seaplaque® low melting point agarose (FMC BioProducts, Rockland, ME, 
USA). After 10 days 4% formalin was laid onto the overlay and left to fix the 
cells for 1 hr at room temperature. Following gentle removal of the overlay, 
the plaques were visualized with a brief staining in 0.2% crystal violet.
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2.14 HAV PURIFICATION.
FRhK-4 cells were infected with 8 x 10  ^pfu/ml of the HM175 strain of HAV 
seed and maintained at 35°C in DMEM maintenance medium. After 10 days 
the supernatant was pooled and centrifuged at 15,000 x g for 20 min to remove 
cellular debris. The infected cell monolayer was scraped into a small volume 
of lysis buffer (10 mM Tris-HCl, lOmM NaCl, 1.5 mM MgCl2, 1% Nonidet 
® P40, [pH7.5]) and incubated on ice for 10 mins followed by three rounds of 
freeze / thawing in a dry ice / 95% ethanol bath. The cell lysate was then 
centrifuged at 15,000g for 20 min to remove cell debris and the supernatant 
added to the clarified medium. This crude viral preparation was pelleted 
through a 20% sucrose cushion in 0.1% Sarkosyl® in TNE buffer (lOmM Tris- 
HCl, 150mM NaCl, l.OmM EDTA) for 20 hr at 100,000 x g on a Beckman 
SW27 ultracentrifuge rotor. The viral pellet was then slowly resuspended in 
0.5% Sarkosyl® in TNE buffer and left overnight at 4°C. The virus suspension 
was then layered onto a 40 ml linear 15 - 30% sucrose gradient prepared in 
TNE buffer containing 0.5% Sarkosyl® and at 86,500 x g on a Beckman SW27 
ultracentrifuge rotor for 4hr at 4°C. 0.5 ml fractions from the gradient were 
collected and tested for the presence of viral antigen using a sandwich ELISA 
(see 2.4). The major viral peaks (see fig. 2.2) were pooled, pelleted at 
250,000g in a Beckman SW50 ultracentrifuge rotor for 2 hr in TNE buffer and 
resuspended in an appropriate buffer. ( Hughes et al, 1984)
2.15 CELL BINDING ASSAYS
Cell monolayers were grown to confluence in 24 - well tissue culture plates in 
the appropriate growth medium. The cells were washed very gently three times 
with PBS and then incubated with a relevant dilution of [125I]- HAV in binding 
buffer ( the appropriate cell medium without FCS [1.8 mM Cat +] ). at 4°C for 2 
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Fig.2.2 Sample sucrose gradients from the purification of HAV. HAV antigen 
detected by sandwich enzyme linked immunosorbent assay (see 2.11). The 
peaks highlighted were kept and used for subsequent assays. Heavier and 
lighter peaks can be observed at different sucrose concentrations and probably 
represent DI particles or aggregations of viral particles.
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ml stoppered plastic test - tubes. The cells were then washed gently three times 
with PBS, saving each wash with the initial inocula. 1M NaOH was then 
added to each well and left for 5 min to ensure complete solubilization, gentle 
agitation was sometimes required. The solubilized cells were then placed in 
plastic test tubes and counted, together with unbound virus on an LKB gamma 
counter. (Krah and Crowell, 1982; Rubio and Cuesta, 1988; Uncapher et al, 
1991 and Kadan et al, 1992)
Inhibition of virus binding was investigated by the pretreatment of the FRhK - 
4 cell surface with various enzymes and lectins and the pretreatment of the 
virus surface with HAV - specific monoclonal antibodies.(see chapters 4 and 5)
2.16 NEUTRALIZATION ASSAY.
The ability of HAV - specific monoclonal antibodies to neutralize the 
replication of HAV was established in the same way as the titration o f HAV by 
plaque assay except that prior to the addition to the cells, aliquots o f virus 
were incubated with 0.6pg/ml monoclonal antibody (mAb) 813,0.22jig/ml mAb
10.09 and 0.33 jig/ml mAb LSHTM/14H ( concentrations of mAbs had yet to 
be established) for 2 hr at 35°C. Neutralization was considered to have 
occurred if  the number of plaques had been reduced by 50 %  or more. 
(Dimmock, 1984; Hughes etal, 1984)
2.17 HAEMAGGLUTINATION
20jj1 of PBS [pH 5.5] ( 30.2mM KH2P 0 4, 119mM NaCl, adjusted to the 
correct pH with NaOH) was placed into a round - bottom microtitre plate. 20p 
1 of l%v/v RBC in PBS [pH 5.5] was added to the well, together with an 
appropriate haemagglutinating dilution of HAV. The plate was then left at 
room temperature for 1 hr, by which time the RBC would have settled if  
haemagglutination had not occurred.
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The number of haemagglutination units (HAU) was then the inverse of the 
haemagglutinating dilution.
Inhibition of haemagglutination was investigated by the pretreatment of the 
RBC cell surface with various lectins and the pretreatment of the virus surface 
with HAV - specific monoclonal antibodies. ( see chapters 3 - 5)( Eckels et al, 
1989)
2.18 VIRUS - RECEPTOR COMPLEX FORMATION.
FRhK - 4 cells were incubated in suspension with [125I] - HAV for 2 hr at 4°C 
in binding buffer. The cells were then washed by centrifugation three times 
and then solubilized in 1% N - octylglucoside for 15 min on ice. The bound 
and unbound HAV were separated on a linear 15 - 30% sucrose gradient and 
fractions containing HAV identified by sandwich ELISA. Alternatively [125I]- 
HAV was incubated in binding buffer for 2 hr at 4°C with FRhK - 4 cell 
presolubilized as above. The resulting suspension was then separated on a 
sucrose gradient as before. These fractions were further investigated by SDS - 
PAGE. (Mapoles et al, 1985; Krah and Crowell, 1985)
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3. HAV BINDING STUDIES
3.1 INTRODUCTION
At the commencement of the project it was generally accepted that the cell 
tropism of HAV was limited to primate cells (Purcell et al, 1984) but the way 
in which this tropism is determined was not known. Information regarding 
binding o f HAV to cells was limited to work by Seganti et al., (1987; 1989) 
which implicated a role for several membrane components including 
phospholipids and glycolipids in the infection of the cell.
Apart from the observation that HAV must bind to red blood cells in order to 
agglutinate them (Eckels et al., 1989), the range of cells that the virus was able 
to bind to was not known. It has been well documented however, that the 
presence or absence of cell specific membrane molecules determine the cells 
infected by several viruses. Human immunodeficiency virus (HIV) for 
instance, infects cells which bear the CD4 molecule (Dalgleish et al., 1984). 
There was a possibility therefore, that HAV could utilize this mechanism of 
specific receptor - mediated entry for determining its cellular tropism. If the 
full binding range of the virus could be determined, then several questions 
regarding its pathology could then be answered.
Firstly, the route of infection in the host could be completed, since the 
mechanism by which the virus passes from the gut to the blood and then to the 
liver had not been confirmed. Poliovirus infects gut cells before causing 
viraemia and subsequent infection of the upper respiratory tract and CNS, 
(Bodian, 1955; Sabin, 1956), so there was a strong possibility that HAV may 
also use gut cells as a primary site of replication.
The ability to identify cell types permitting binding could then be used to 
support this' gut replication' hypothesis. In addition it may also be used to 
explain a second observation, that patients suffering from fulminant hepatitis A
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virus infections who undergo a liver transplant may suffer a reinfection o f the 
transplanted liver, indicating that, in vivo, the virus is able to replicate in cells 
other than hepatocytes (Fagan et al., 1990).
As well as knowing little about o f the range of binding tropism HAV exhibited, 
there was no information regarding other aspects of the cellular receptor for the 
virus, such as the kinetics o f the interaction, and the receptor copy number on 
permissive and non-permissive cells. This was particularly relevant as it would 
shed more light upon its distribution (e.g. widespread occurrence of the 
receptor might imply a common molecule, highly conserved amongst a range of 
cell types) and may answer questions as to the extremely poor replication of 
HAV in tissue culture, Wheeler et al., (1986a) observed that HAV is not 
efficiently uncoated in tissue culture, with a substantial proportion of the 
inoculum being recovered 12 hours after infection.
A series o f binding experiments were therefore devised to investigate these 
questions.
RESULTS AND DISCUSSION
3.2 BINDING OF HAV TO CULTURED CELL MONOLAYERS
3.2.1 Temperature
The first experiment was designed to optimise the temperature for the binding 
o f virus to cells. This was an important consideration, since the capping of 
cellular receptors and the resulting reduction in the number of available virus 
binding sites at 37°C has already been suggested (Zajac et al., 1991).
Therefore any estimation as to the number of receptor sites would be inaccurate 
if  capping of the HAV cellular receptor takes place. In addition, at 37°C 
membrane proteins are dynamic and are constantly being internalized and 
recycled. The kinetics o f such an experimental arrangement would be highly 
complex and difficult to interpret. Therefore it would be more convenient if
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binding assays could be performed at a temperature at which internalization 
was reduced to a minimum or abolished altogether.
Therefore a comparison of binding at two temperatures, 4°C and 35°C was 
performed under the same conditions as described in section 2.15 (Fig. 3.1).
The results show that after a two hour incubation more virus is bound at 4°C 
than at 35°C. There are three possible explanations; Firstly, that receptor 
capping has indeed taken place at the higher temperature, secondly, that the 
interaction between the inoculating virus and the cell surface has not reached 
equilibrium because the virus is being internalized (the iodinated virus proteins 
would subsequently be recycled and lost from the cell), and lastly that at 35°C 
the interaction between virus and receptor is not stable with a low resulting 
binding constant. These three points will be addressed in the discussion.
The conclusion from this experiment was that binding experiments should be 
performed at 4°C.
3.2.2 Binding Kinetics
Having optimised the binding temperature, the next step was to attempt to 
saturate an FRhK-4 monolayer with iodinated virus. This was undertaken for 
several reasons. Firstly it was the most convenient way o f ensuring that the 
binding of HAV to this cell line was specific. If the monolayer proved to be 
unsaturable this would indicate that the binding observed in these experiments 
was not necessarily specific , since non-specific binding between a ligand and 
a cell surface is unsaturable. Secondly the saturation curve obtained from these 
experiments would confirm whether binding of virus and cell receptor was of a 
simple ’Michaelis-Menton1 type, with one virion binding for every one receptor 
molecule. This form of interaction would result in data that would fit to an 
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Fig. 3.1 Comparison of 125I - HAV binding to FRhK - 4 cells (2.5 x 105 cells 
/datapoint) at 4°C (—v—) and 35°C for 2 hrs, in binding buffer [1.8 mM
Ca ], Bars represent range of duplicate results obtained. Curves described by 
equation (3) in section 3.2.2 are fitted to the data. Specific activity of the virus is 2.2 
x 106 cpm/gg.
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B  B p “  1 ( 1 )
I +  ko.5
Where, B = bound [123I]-HAV, I = input [,25I]-HAV and K0 5 = input virus at 0.5 
x Bmax
Lastly, this type of binding assay would give an indication of the number of 
binding sites on each permissive cell, which may in turn indicate how common 
a molecule the cellular receptor is. For instance, the number of sialic acid 
molecules on a mammalian cell surface will be very high, whereas CD4 
molecule numbers may be very low.
Fig. 3.2 shows a plot of the data obtained from the saturation of an FRhK-4 
cell monolayer. Having attempted to fit a curve described by the Michaelis - 
Menten equation, it was obvious that the interaction under investigation did 
not follow classical Michaelis-Menten kinetics.
Instead of a rectangular hyperbola, the data in Fig. 3.2 seems to follow a 
sigmoidal curve.
This type of curve can be indicative of an allosteric mechanism, whereby the 
binding of one ligand to a receptor molecule increases the affinity o f the same 
receptor for a second ligand. We therefore attempted to fit a curve to the data, 
which describes such an interaction using the Pfit curve fitting program 
supplied with FigP (Biosoft) scientific graph package (Fig. 3.2) The curve is 
described by the following equation,
n  =  Ih
I h +  ko.5 ( 2 )
Where, B = bound [125I] - HAV, I = input [125I] - HAV, = input [125I] - HAV
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Fig. 3.2 Saturation of an FRhK-4 cell monolayer (2.5 x 105 cells/datapoint) with 
[125I] - HAVat 4°C for 2hr in binding buffer [1.8mM Ca^]. A curve described by the 
Hill equation for allosteric interactions is fitted to the data. Bars represent range of 
duplicate results.
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B = 5039 cpmmax ^
kjj j =47716 cpm 
h =2.17
As can be seen the curve described by this equation fits the data well, though 
no definitive ’closeness o f fit’ can be given.
To confirm that HAV binding to FRhK-4 cells did not follow classical 
Michaelis-Menten binding kinetics, a second plot was constructed (Fig. 3.3). 
This Scatchard plot (Scatchard, 1949 ) will linearize single-site binding 
kinetics data by plotting the following,
b°— £  I] -HAV AGAINST bound ['“ I] -HAV (3) 
free [,251] -HAV w
As can be seen in fig. 3.3, however, this plot is not linear and thus confirms 
that the interaction of HAV with its cellular receptor does not follow simple 
kinetics.
Initially, the mechanisms behind such kinetics were difficult to envisage since 
the interaction of a ligand of « 8 x 106 Da with a cell surface receptor was 
under study. Two possible explanations have been considered. Firstly, if  the 
aggregation of HAV is in fact a dynamic event, with dissociations as well as 
associations, and the affinity o f virion for virion is greater than that of receptor 
for virion, then it is possible that the binding of a single virion to the cell 
surface apparently increases the affinity o f a second virion for the cell surface, 
via the bound virion.
The second explanation is based on data recently obtained by Anderson et al 
( Meeting Abstract, 1992). This group have isolated a putative cell binding site 
for HAV, showing it to be a homodimer o f 200kDa. They have also shown that 
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Fig. 3.3 Scatchard plot of the saturation of an FRhK-4 cell monolayer (2.5xl05 
cells/datapoint) with [125I]-HAV at 4°C for 2hr in binding buffer [1.8 mM Ca2+]. 
Specific activity is 2.2 x 106 cpm/gg.
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to explain an allosteric interaction of HAV and its receptor, since if  their 
findings are correct there are two binding sites on each receptor dimer.
3.2.3 Binding Tropism of HAV
Having confirmed that a specific interaction is taking place, the next phase of  
the project was to examine the range of the binding tropism of the virus. To 
this end, under exactly the same conditions, the binding of [125I] -HAV to three 
different cell lines, FRhK-4, CHOandWRC was compared, as a prelude to 
more extensive studies. As can be seen in figs.3.4 - 3.5, the binding curves for 
the CHO and WRC cell lines show equal or greater binding to that o f FRhK-4 
cells. This has several implications. Firstly, if  the possession of a particular 
binding molecule was the sole determinant of tissue tropism, it would be 
expected that binding would only occur to FRhK-4 cells and not to CHO and 
WRC. This is plainly not the case so other determinants o f tropisms must be 
considered. Tissue tropism may still be determined at the cell surface, but not 
solely by the presence or absence of certain binding molecules. Herpes 
simplex virus, as an example, will bind to cells bearing the heparan sulphate 
moiety, which is common to all mammalian cell types. Tissue tropism 
however, is thought to be governed by the possession of a second type of 
plasma membrane molecule, which is involved in internalization of the virus 
(Johnson et al., 1990). The second possibility is that HAV is internalized by all 
cells which bear its cellular receptor, and that it is the intracellular elements of  
its replication which determine whether progeny viruses will be produced. 
Examples of such determinants include endosomal pH or host cell ribosome 
specificity. The investigation of the range of binding tropism of HAV was 
extended to a haemagglutination assay (Fig. 3.6) where HAV was found to 
bind to red blood cells. The notable feature o f this is that the 
haemagglutination assays were performed in PBS at a pH of 5.5, devoid of  
divalent cations, which have been shown to be essential for the binding of 
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Fig. 3.4 Comparison of the binding of [125I]-HAV to FRhK-4 (—v—) and 
CHO (--□—) cells (2.5 x 105 cells / datapoint) at 4°C for 2 hr in binding buffer 
[1.8 mM Ca2 ]. Bars represent range of duplicate results. Curves descibed by 
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Fig. 3.5 Comparison of the binding of 125I-HAV to FRhK-4 (—v—) and WRC 
(--□—) cells (2.5 x 105 cells/datapoint) at 4°C for 2hr in binding buffer [1.8 mM 
Ca2+]. Bars represent range of duplicate results. Curves described by equation 






















P U R I F I E D  V I R U S  P R E P A R A T I O N S
3.6 Agglutination of red blood cells with various preparations of purified 
HAV in PBS [pH 5.5] at room temperature.
The implications of all o f these points will be considered in the discussion 
(chapter 6).
3.3 VIRUS - RECEPTOR COMPLEX
As well as gaining some knowledge about the interaction of HAV with various 
cell lines, attempts were made to purify the receptor. This would allow study 
of the structure of the receptor such as N-terminal sequence determination, 
which are not possible with cell bound proteins. At the start o f the project there 
was very little information available about the makeup of the receptor in terms 
of molecular weight, pi and other parameters which would make purification 
possible. The only two techniques available were therefore the production of a 
monoclonal antibody to the receptor using a cell protection assay as a screen 
or to use the virus itself as an affinity ligand to co-purify the receptor with the 
virus (Mapoles et al., 1985). Production of a monoclonal antibody was 
considered to be too time consuming, since the only available source of 
receptor was whole cells. This would mean screening numerous clones in 
order to obtain one directed against the epitopes on the receptor. As a result, 
the latter technique was used.
Since the amount of purified virus available was limited, it was unacceptable 
to use any method which did not make the best use of the virus. Mapoles et al., 
1985 perfected a method for purifying the cellular receptor o f Coxsackie B3 
virus (another Picomavirus), which entailed the separation, on a sucrose 
gradient, o f free virus from virus bound to its cellular receptor. It is this 
procedure upon which the attempted copurification o f the cellular receptor for 
HAV was based.
[123I] - HAV was incubated in binding buffer [1.8mM Ca2+] for 2 hr at 4°C, with 
FRhK - 4 cells which had been solubilized in 1% n-octylglucoside and left on 
ice for 15 min. The cell/virus suspension was then carefully layered onto a 
continuous 15 - 45% sucrose gradient, and ultracentrifuged for 3 hr at 4°C at
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86,500 x g using a Beckman SW27 ultracentrifuge rotor. Fractions of 0.5ml 
were collected from the gradient, and the presence of [125I] - HAV was 
detected by counting on an LKB gamma counter. Figs. 3.7 - 3.9 show the 
resulting gradients, and indicates that a proportion o f [125I]-HAV has 
sedimented at a faster rate than control virus alone. There can be no doubt that 
there is viral antigen present in this higher molecular weight fraction, since the 
viral proteins have been radiolabelled with [125I] which suggests that the virus 
has associated with some component of the FRhK-4 cell membrane. Points A  
and B represent two possible positions where a complex of virus and receptor 
may have occurred. Anderson et al, 1992 (Meeting abstract) proposed that a 
virus - receptor complex under these conditions would appear as a shoulder on 
the main uncomplexed virus peak (peak B). Point A may represent an 
aggregation of HAV associated with, and mediated by cellular components. 
Though these methods can certainly be improved by optimising conditions for 
the production of virus-receptor complex and subsequent isolation, the results 
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Fig. 3.7 Profile of a sucrose gradient to separate ,25I-HAV and 125I-HAV- 
receptor complex having incubated labelled virus with BSC-1 cells (solubilized
in 1% N-octylglucoside) in binding buffer for 2 hr at 35°C. (....... ) represents
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Fig 3.8 Profile of a sucrose gradient to separate ,25I-HAV and 123I-HAV- 
receptor complex having incubated labelled virus with BSC-1 cells (solubilized
in 1% N-octylglucoside) in binding buffer for 2 hr at 4°C. (....... ) represents
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Fig. 3.9 Profiles of a sucrose gradient to separate 125I-HAV and 125I-HAV- 
receptor complex having incubated labelled virus with FRhK-4 cells
(solubilized in 1% N-octylglucoside) in binding buffer for 2 hr at 4°C. (.......)
represents virus receptor complex isolation, (—) represents virus only control. 
Points A and B represent possible fractions where a virus-receptor complex 
may reside.
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4. HAV - SPECIFIC MONOCLONAL ANTIBODIES
4.1 INTRODUCTION
Previous work on this area of HAV virology is far more extensive than has 
been described for the kinetics o f HAV binding or for the structure of the 
cellular receptor. This was mainly due to the fact that a effective vaccine for 
HAV had not been established, so it was important to gather information 
regarding the interaction of HAV with HAV - specific monoclonal and 
polyclonal sera. There were many HAV - specific antibodies available in 
various different laboratories (Ping and Lemon, 1992), though only three 
monoclonals have been investigated in this study; LSHTM /14H, 813 and
10.09 (Crevat et al, 1990), and a convalescent serum IgG fraction. These 
monoclonal antibodies had been previously used by Ping and Lemon, (1992) to 
establish the antigenic structure of the virus, by the production and sequencing 
of mutants which had escaped the antibodies' neutralization properties. In the 
process they had gathered data regarding the cross reactivity and neutralization 
potential of the antibodies. They had shown that 813 and 10.09 reduced the 
binding of an iodinated polyclonal antibody to about 52%, whereas 14H 
reduced its binding to 64%. They also showed that 813 and 10.09 almost 
completely neutralized HAV in a radioimmunofocus assay, whereas 14H could 
only reduce radioimmunofoci by up to 50%.
Another important observation regarding the antigenicity o f HAV is that there 
only appears to be one wild-type serotype virus (Ping and Lemon, 1992), 
indicating that to escape antibody neutralization by polyclonal sera, the virus 
would have to mutate in such a way that it was no longer viable. This in turn 
suggests that the site o f neutralization for HAV is extremely important for 
replication.
79
There was however, no detailed information regarding the mechanisms behind 
the neutralization of HAV, although the subject of virus neutralization had 
been addressed by many different groups (for review see Dimmock, 1984). 
One possible mechanism that had been put forward was virus neutralization by 
antibody - mediated inhibition of binding. This would occur by the antibody 
competing with the cellular receptor for binding to the virus, and could be used 
to explain why HAV can only maintain one serotype virus.
It was decided therefore that a series of experiments would be undertaken to 
investigate whether this was true for HAV.
RESULTS AND DISCUSSION
4.2 NEUTRALIZATION OF HAV
Firstly, the ability or inability of the three monoclonal antibodies (MAbs) 
LSHTM/14H, 813 and 10.09 to neutralize the virus was confirmed by 
incubating infectious virus with 1.5 pg/ml of each of the antibodies in PBS for 
2hr at 35°C, prior to the addition of the virus to a standard plaque assay. Table
4.1 shows the reduction in plaque numbers after the virus had been 
preincubated with MAbs 813 and 10.90. In contrast, no such reduction is 
observed in the virus preincubated with MAb LSHTM/14H; indicating that this 
monoclonal antibody is unable to neutralize HAV. This agrees with the results 
obtained by Ping and Lemon, (1992), and indicates that these antibodies 
represent a system by which the site o f virus neutralization may be ascertained.
4.3 COMPETITION RADIOIMMUNOASSAY.
If the virus is neutralized by the binding of antibodies to the cell binding site, it 
would be reasonable to assume that the non-neutralizing antibody, 14H fails to 
neutralize because it does not interact with these sites. There would therefore
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Monoclonal Antibody Plaque Number
Control 27 (± 8)
14H 22 ( ± 2)
813 i ( ± i >
10.09 2 ( ± 1)
Mock Infected 0
Table 4.1 Reduction o f plaque number by the preincubation of infectious 
HAV with neutralizing and non-neutralizing monoclonal antibodies prior to 
inoculation of an FRhK-4 cell monolayer.
be a possibility that, whereas 813 and 10.09 will compete for binding to the 
virus capsid, 14H will not compete with either of the other two antibodies.
This would actually be a simplistic view of the possible events since a non­
neutralizing and neutralizing antibody may still compete with each other whilst 
not necessarily both blocking binding of virus to cell.
To ascertain whether 14H, 813 and 10.09 would compete for binding to the 
cell, a competition binding assay was performed ( see 2.1 0 ) between [125I]-
10.09 and each of the monoclonal antibodies and an anti-HAV convalescent 
IgG fraction. Fig 4.2 demonstrates how MAb 813 and 10.09 reduced binding 
of [125I]-10.09 to around 48%, whereas LSHTM/14H reduced the binding of 
the labelled antibody to only 76%. The convalescent IgG fraction also reduced 
binding by around 50%. Since the concentrations of all the monoclonal 
antibodies in the assay are the same, these results suggest that monoclonal 
antibodies 813 and 10.09 compete for the same epitope on the virus capsid.
The result for monoclonal antibody LSHTM/14H, however, suggests that it is 
binding to an epitope sufficiently distant from the binding sites of 813 and
10.09 to allow the labelled antibody [125I]-10.09 to still bind. These results 
agree, in principle, with those of Ping and Lemon, (1992) which indicated that 
14H did not interfere with the binding of a polyclonal antibody to the same 
extent as 813 and 10.09 (14H reduced binding to 64% whereas 813 and 10.09 
reduced binding to 52%). Both the data o f Ping and Lemon, 1992 and the data 
presented here therefore agree with the general hypothesis of discrete, (but 
overlapping?) epitopes utilized by neutralizing and non-neutralizing antibodies. 
It must be emphasized however, that Ping and Lemon, 1992 attempted to block 
the binding of a polyclonal antibody with 813, 10.09 and 14H, as in contrast to 
these results, which describe the inhibition of binding of the neutralizing 
monoclonal antibody 10.09. The primary consequence of this is that residual 
binding of the iodinated polyclonal would still be expected even after saturation 





Fig. 4.2 Competition radioimmunoassay between 125I-labelled HAV - specific 
monoclonal antibody 10.09 and HAV - specific antibodies 14H, 813, 10.09 
and an IgG fraction of convalescent sera to HAV. Maximal binding (100%) 
lOOOcpm.
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Having obtained these results it was important to confirm the hypothesis of 
antibody neutralization at the cell binding site, by directly measuring the effect 
o f these antibodies on HAV - cell interactions.
4.4 INHIBITION OF HAEMAGGLUTINATION
Having established the neutralization properties o f the three HAV - specific 
monoclonal antibodies, and how they apparently behaved in a competition 
assay, the next step was to investigate the ability o f the monoclonal antibodies 
to interfere with virus binding to cells. As has been reported previously, HAV 
binds to various different cell lines. In the case of red blood cells this causes 
haemagglutination. This represents a possible model for the investigation of 
virus binding to cells, and therefore can be used to investigate the inhibition of 
binding by monoclonal antibodies.
2 haemagglutination units (HAU) o f HAV were pre - incubated with doubling 
dilutions o f MAbs LSHTM/14H, 813, 10.09 or a convalescent sera IgG 
fraction, for 2hr at 37°C before being added to RBC in a standard 
haemagglutination assay ( see 2.18 ).
Fig 4.3 and table 4.4 reveal how MAbs 813 and 10.09 have inhibited 
haemagglutination to a titre o f 480 and 1920 respectively by inhibiting binding 
o f the virus to the red blood cells. MAb LSHTM/14H however, did not inhibit 
haemagglutination even at a titre o f less than 15 indicating that it is unable to 
interfere with virus binding to red blood cells.
The suggestion that neutralizing and non - neutralizing antibodies have 
different effects on HAV - mediated haemagglutination has not previously been 
observed and adds further evidence towards the hypothesis that neutralizing 
antibodies neutralize by binding to an epitope on the virus sufficiently close to, 
or on, the cellular binding site. This is reinforced by the observation that the 
non - neutralizing antibody has no effect on binding o f virus to RBC, and so is 
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H A E M A G G L U T I N A T I O N  T I T R E
Fig. 4.3 Inhibtion of HAV - mediated haemagglutination by preincubation of 
HAV samples with HAV - specific antibodies.




Monoclonal 14H 0.33 <15
Monoclonal 813 0.60 480
Monoclonal 10.09 0.22 1920
Convalesent IgG fraction 0.88 960
Table 4.4 Inhibtion of HAV - mediated haemagglutination by preincubation of 
HAV samples with HAV - specific antibodies.
4 0  8 0  DOUBLING DILUTIONS
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4.5 INHIBITION OF BINDING TO A PERMISSIVE CELL LINE.
The results obtained in section 4.4 suggested that the neutralization of HAV by 
monoclonal antibodies takes place as a result o f those antibodies sharing their 
epitopes with the cell binding site o f the virus. Though the use of red blood 
cells represents a convenient way to investigate virus - cell interaction, it is 
still necessary, ultimately to confirm the results by attempting to inhibit virus 
binding to a cell line known to be infected by HAV in tissue culture.
To achieve this, [125I]-HAV was incubated with 1.5pg/ml o f each of the three 
monoclonal antibodies, for 2 hr at 37°C. Following this a standard binding 
assay was performed (see section 2.15).
As can be seen in Fig. 4.5, each of the monoclonal antibodies investigated has 
all but abolished binding o f HAV to the FRhK-4 cells.
One possible explanation for the apparent contradiction between the 
haemagglutination inhibition assays and these binding inhibition assays is that 
the receptor present on red blood cells is not the same as on FRhK-4 cells; as is 
the case with influenza virus, where haemagglutination inhibition by 
monoclonal antibodies occurs but inhibition of binding to permissive cells does 
not. Though, with the available data it is difficult to construct a model for 
these events, it is conceivable that the receptor on FRhK-4 cell is less sterically 
available than the receptor on red blood and other cell types. As a result, 
though the presence o f monoclonal antibody 14H interferes with virus binding 
to FRhK-4 cells, perhaps the greater availability o f the red blood cell receptor 
means that the hindering action of this monoclonal antibody is not so evident. 
The action of monoclonal antibodies 813 and 10.09 is as would be predicted, 
apparently interfering with binding by attaching to the cell binding site o f the 
virus or interfering with the function of this site by allosteric effects.
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Pos 14H 813 10.09
Inhibitor
Fig. 4.5 Inhibition of ,25I-HAV binding to an FRhK-4 cell monolayer by the 
preincubation of the virus with HAV - specific monoclonal antibodies 14H, 
813 and 10.09. Maximal binding of positive control (100%) 85cpm.
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5. BINDING INHIBITION STUDIES
5.1 INTRODUCTION
One way of elucidating the structure o f a virus's cellular receptor is to treat the 
receptor or the virus in a way which interferes with the binding. This may 
mean treating the whole cell or cell membrane with enzymes, or incubating 
them with compounds which will compete with the virus for the binding site. 
Alternatively it may involve incubating the virus with compounds which 
compete with the cellular receptor for binding o f the virus, which may also 
give clues as to the structure of the receptor.
This approach had been successfully used for several virus receptors. The 
receptor for influenza virus, sialic acid, was discovered by treating red blood 
cells with neuraminidase prior to a haemagglutination assay, resulting in 
complete inhibition of haemagglutination (Bumess and Pardoe, 1981).
The primary binding site for herpes simplex virus, heparan sulphate, was 
determined when it was observed that heparin bound to the virus and inhibited 
binding and infection (WuDunn and Spear, 1989).
As was mentioned in chapter 3, Seganti et al., (1987; 1989) used these 
methods to gather a limited amount o f information as to the structure o f the 
cellular receptor for HAV. This group found that the virus binding site on 
Frp/3 cell membranes was sensitive to trypsin, phospholipase and p - 
galactosidase (Seganti et al., 1987), whilst binding could also be inhibited by 
incubating the virus with various membrane lipid components, specifically 
those bearing galactose residues (Seganti et al.,. 1989). The conclusion at the 
time was that the receptor for this virus is extremely complex, with proteins, 
phosphatidlyserine, phosphatidylethanolamine and galactose participating in 
vims binding. Unfortunately these studies only detected inhibition o f binding 
by measuring inhibition of infection (fluorescence - linked immunoassay). This
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did not, however, address the question of whether the initial virus binding site 
is the only component required for virus infection of permissive cells. In these 
studies, this question was met by investigating inhibition of virus binding 
rather than inhibition o f virus infection. This involved treatment o f the cell 
surface with various enzymes, and incubation of vims with compounds which 
mimic the virus binding sites on the cell surface. In addition, the cell surface 
was incubated with lectins. Lectins are naturally occurring proteins which bind 
to specific short oligosaccharide sequences, and can therefore be used to 
determine what, if  any, sugars take part in vims binding. Lectins were used 
by Krah and Crowell (1985) to inhibit the binding of group B Coxsackieviruses 
to solubilized HeLa cell membranes.
5.2 ENZYMATIC INHIBITION OF BINDING
Three enzymes were used to treat the surface of the cell and subsequently 
observe the effect on binding. Trypsin was the first choice, to confirm the 
involvement o f proteins, since trypsin, a serine protease, specifically cleaves 
proteins at arginine and lysine residues. The second, neuraminidase, was used 
to cleave off sialic acid residues on glycoproteins, to determine whether these 
moieties were involved, a common occurrence with other viruses such as 
influenza vims. Finally endoglycosidase F was used, since this enzyme 
specifically removes oligosaccharide residues from N - linked glycoproteins 
and so would indicate a role for glycoproteins in the interaction.
106 FRhK-4 cells were scraped into cold PBS, spun at 1000 rpm for 2 min, 
and washed twice to remove residual FCS. The cells were then resuspended in 
the following enzyme solutions; Vibrio cholerae neuraminidase (0. lU/ml) 
(Boehringer Mannheim, Mannheim, Germany), for 2.5 hr at 37°C in PBS; 
Endoglycosidase F (0.4 U/ml) (Boehringer Mannheim), for 2.5 hr at 37°C in 
PBS; or trypsin (0.5 mg/ml) for 10 min at room temperature. Following three 
washes, the cells were incubated with 8000 cpm of [125I] - HAV for 2 hr at
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4°C in binding buffer. The virus was then removed, but retained, as were the 
subsequent three washes. The amounts o f bound and unbound virus were then 
established by counting in an LKB gamma counter. Table. 5.1 shows that the 
digestion o f proteins by trypsin inhibits HAV binding which suggests that 
proteins play a part in the binding of HAV to its target cell (in this case 
FRhK-4 cells). It does not however, provide any details as to the type of 
protein it may be. The fact that binding o f virus is not completely abolished is 
almost certainly due to the incomplete removal o f proteins from the cell 
surface. This may have occurred for several reasons. Firstly, since the 
complete removal o f proteins would have resulted in the lysing o f the cell, 
which in turn would have flawed the experiment, a lesser degree of 
deproteination was considered acceptable. Secondly, because of the 
autodegradative properties o f trypsin, it may not have removed all proteins 
from the cell surface in the short incubation period. The third, and most 
contentious possibility, is that HAV relies, for binding, on moieties that are 
present on proteins, but are also present on other cell surface molecules, such 
as certain sugar residues. The neuraminidase result proved far from conclusive 
but suggests that sialic acid does not play a part in virus binding. The result of 
endoglycosidase F pretreatment o f the cell surface suggests that the receptor 
protein is not an N - linked glycoprotein. This result however, may be 
misleading as this enzyme may, in some cases, work poorly with folded 
proteins.
5.3 INHIBTION OF HAEMAGGLUTINATION (HA)
Following the results o f the enzyme pretreatment o f the cell surface, more 
detailed analysis o f the relevant residues on the cell surface was undertaken, 
with the use o f lectins. Lectins specifically recognize and bind to sugar 
residues, and together with the ability o f HAV to bind to and agglutinate red 
blood cells, could be used to determine more information about the role o f
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NEURAMINIDASE ENDOGLYCOSIDASE F
Fig. 5.1 Inhibition of ,25I-HAV binding to FRhk-4 cells by enzyme 
pretreatment of the cell surface. FRhK-4 cells were treated with 0.5mg/ml 
trypsin for 10 min at room temperature, Vibrio cholerae neuraminidase at 35°C 
for 2.5 hr or endoglycosidase F at 35°C for 2.5 hr and then incubated with 8000 
cpm ,25I-HAV at 4°C for 2 hr in binding buffer.
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sugar residues in binding. This was accomplished in a series of 
haemagglutination inhibition (HAI) assays.
Prior to haemagglutination, the red blood cells (RBC) were incubated for lhr 
at room temperature with dilutions o f lectins from Arachis hypogaea 
(100 pg/ml) or Lotus tetragonolobus (lOOpg/ml) in PBS [pH 5.5]; and the 
effects on haemagglutination noted. Table 5.2 shows that Lotus tetragonolobus 
lectin inhibited viral haemagglutination. This lectin is specific for fucose 
attached via a a  1 - 6 linkage to N - acetylglucosamine on N - linked 
glycoproteins, and suggests that this moiety may play a part in virus binding to 
the red cell membrane. Arachis hypogaea lectin however, failed to inhibit 
haemagglutination, suggesting that the complex sugar residue, Gal p i - 3 
GalNAc (preferentially to a  Gal) which it recognizes, does not represent an 
important site for virus binding. This latter result is unexpected since it 
disagrees with the findings o f Seganti et al. (1987) who proposed a role for 
galactose residues in virus bindings.
To follow up these results, we attempted to inhibit haemagglutination with 
porcine thyroglobulin (a large glycoprotein known to be fucosylated), and 
fucose, in an attempt to compete with the cell receptor for HAV binding. In 
addition, haemagglutination inhibition was also attempted with foetal calf 
serum, since Zajac et al (1991) suggested that FCS interfered with virus 
binding to susceptible cell lines; and heparin to see if  HAV shares a cell 
binding site with herpes simplex virus. Thus, HAV was incubated with 
dilutions o f porcine thyroglobulin (lOOpg/ml - lOpg/ml), L - fucose (lOOpg/ml 
- lOpg/ml), foetal calf serum (10% - 0.00064%) and heparin (lOOpg - lOpg/ml) 
each in PBS [pH 5.5] prior to a haemagglutination assay. Table 5.3 goes some 
way to confirming the hypothesis that fucose is involved in binding.
At a concentration o f 1 jLig/ml or greater, the porcine thyroglobulin has 
saturated the cell binding sites on the virus, abolishing binding o f virus to the 





Table 5.2 Inhibition of HAV - induced haemagglutination by lectins. 
(- denotes no haemagglutination, + denotes haemagglutination).
Foetal calf serum (%) IQ 2 4xl0-i
©X00 1.6x l0-3 3.2x10^1
- - - + + +
Porcine thyroglobulin 100 10 I lxlO-i lxlO-2 lxlO-3
(mg/ml) - - - + + +
L - fucose (mg/ml) + + + + + +
Heparin (mg/ml) + + + + + +
Table 5.3 Inhibition of haemagglutination by various agents. (- denotes no 
haemagglutination, + denotes haemagglutination).
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position o f the fucose molecule within the glycoprotein may also be important. 
As would be predicted from the results o f Zajac et al, (1991) FCS inhibited 
haemagglutination down to a concentration o f 0.4%. The failure o f heparin to 
inhibit haemagglutination indicates that heparan sulphate does not compete 
with the cell for binding to the virus, and suggests that this cell surface moiety 
does not play a part in virus binding.
5.4 INHIBITION OF VIRUS BINDING TO CELLS WITH LECTINS
Having determined the effects o f lectins on HAV - induced haemagglutination, 
it was necessary to investigate the effects o f the same conditions on virus 
binding to FRhK-4 cells. This was primarily undertaken to discover whether 
or not red blood cells represent an adequate model for the binding of HAV to 
FRhK-4 cell monolayers.
Confluent monolayers o f FRhK-4 cells in a 24 - well plate were gently washed 
twice in PBS and incubated for 1 hr at room temperature, with the following 
lectin solutions; Arachis hypogaea (100 pg/ml), Lotus tetragonolobus (lOOp 
g/ml), Triticum vulgare (lOOpg/ml), or Lens culinaris (lOOpg/ml), and then 
gently washed three times in PBS. 8000 cpm [123I]-HAV in binding buffer [1.8 
mM Ca2+] was added to each o f the wells. All wells were then left for 2 hr at 4° 
C. The labelled virus was then removed, but retained in 4 ml stoppered plastic 
test - tubes, as were the subsequent three PBS washes. The cells were 
solubilized in 1M NaOH, and placed in plastic test tubes. The results were then 
counted using an LKB gamma counter. Table 5.4 shows the effects o f lectins 
on virus binding. It appears that the results obtained for the haemagglutination 
inhibition by lectins cannot be reflected in binding inhibition. This may mean 
that the inhibition of haemagglutination by fucose - specific lectins is not as a 
result o f its specificity for fucose, but by general steric hindrance. The 
alternative is that the specificity for fucose is relevant, but that the receptor on
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Lectin % Binding
Control 100 ± 9
Lens culinaris 149 ±21
Triticum vulgare 82 ± 13
Limulus 142 ± 9
Arachis hypogaea 100 ± 13
Lotus tetragonolobus 79 ±28
Fig. 5.4 Inhibition o f 125I-HAV binding to FRhK-4 cells by pre-incubation of 
the cell surface with lectins. 8000 cpm of 125I-HAV was incubated with 100 m 
g/ml o f various lectins for 2 hr at 35°C. The virus was then incubated for 2hr 
at 4°C with a monolayer of FRhK-4 cells. The degree of binding was then 
established as has been described. Maximal binding (control 100%) 85cpm.
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red blood cells is able to bind HAV whilst being different from the receptor on 
susceptible cell lines such as FRhK-4.
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6. DISCUSSION
6.1. HAV BINDING STUDIES 
Temperature Dependence
To optimize the binding o f HAV to FRhK-4 cells, binding was compared 
between two temperatures, 4°C and 35°C. This was undertaken because all 
binding experiments were to be performed on unfixed live cells, to more 
accurately reflect in vivo conditions. The complication with this approach is 
that at physiological temperatures virus is rapidly internalized, leading to 
complex kinetics and difficulties with interpretation of data. To overcome this 
it would be more convenient to perform assays at 4°C, where membrane 
fluidity and virus internalization is greatly reduced. This would allow 
equilibrium between virus and receptor to be established.
As well as simplifying conditions, it has also been shown that other viruses 
apparently bind better at lower temperatures (Joklik and Darnell, 1961; 
Fenwick and Cooper, 1962 and Crowell and Philipson, 1971) resulting in a 
more sensitive assay. This may be due to the fact that at 35°C membrane 
receptor proteins are not as evenly dispersed as they are at 4°C. Consequently 
there are less available binding sites on the cell surface, or the ability o f the 
virus to bind has been reduced. For all o f these reasons it was important to 
perform the investigation shown in section 3.1.
The results shown in Fig.3.1 show that more virus is bound at 4°C after 2 hr 
than at 35°C, a result later confirmed by Zajac et al, (1991). This would 
indicate that either receptor capping has taken place to such an extent that all 
available binding sites are saturated after a 2 hour incubation at 35°C, that 
virus is being internalized and viral proteins recycled or that the interaction of 
virus and receptor is more stable at 4°C than 37°C. To completely remove the 
possibility o f receptor capping, cells could be fixed with 80% acetone to halt
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internalization, prior to saturating the monolayer with [125I]-HAV and 
comparing the resulting B ^w ith that obtained from the saturation curve 
obtained with [125I]-HAV binding to unfixed cells at 4°C.
The effect that an increase in temperature apparently has on binding may add to 
the many possible explanations as to why HAV replicates so poorly in tissue 
culture. The accepted method for the infection of a monolayer with HAV is to 
incubate the monolayer with virus in PBS for 2 hr at 35°C. This, in light o f the 
results obtained in section 3.1, may not be the most efficient way. One route 
o f investigation that may yet be explored is to compare yields o f HAV from 
monolayers infected at 4°C and 35°C. If these results reflect the in vivo 
condition, it would be expected that a lower m.o.i. is required at 4°C to 
obtained the same yield. These results should agree in principle with the Bmix 
estimation as described above.
As a consequence o f the obtained results all subsequent binding experiments 
were undertaken at 4°C.
Cellular Tropism
The host range of HAV is generally regarded as very limited, being confined 
to cell lines o f primate origin. Information regarding the cell types the virus 
infects (e.g. epithelial, fibroblastic) was, and still is, less clearly defined, with 
reports o f virus antigen recovered from kidney, epithelial, lymph node and 
hepatocyte tissue (Fagan et al, 1990) as well as cultured cells which are not 
generally permissive to HAV (Day, personal communication). There were 
however, no data concerning the virus's binding tropism, though initially we 
assumed that binding tropism would be limited to cells that the virus is known 
to infect. It was therefore considered important to begin to investigate the 
binding range o f the virus to try and see if  this assumption was correct.
The results obtained in section 3.2 suggest that our assumption was not correct, 
with similar binding curves obtained with FRhK-4, CHO and WRC cells as 
well as the agglutination o f erythrocytes by various preparations of HAV. This
98
would at first indicate that the possession or absence of a specific receptor by a 
cell does not dictate which cells the virus infects.
Unfortunately, as is often the case with HAV (as a result o f its tendency to 
form non-specific interactions), it has yet to be established whether or not 
binding o f HAV to CHO, WRC and red blood cells is of a specific nature. This 
question is o f considerable importance, as its answer would indicate whether 
or not the initial cellular receptor - virus interaction could still mediate cell and 
tissue tropism. This data could be obtained by successfully saturating a 
monolayer o f CHO or WRC cells, or blocking binding with the use o f HAV - 
specific neutralizing monoclonal antibodies. In addition, Anderson et al 
(Meeting abstract) have recently copurified a putative cellular receptor for 
HAV with bound virus, and are in the process o f isolating it. Once sufficient 
amounts have been purified then some sequence analysis can take place. This 
sequence information could then be used for, amongst other things, the full 
determination of the distribution o f the cellular receptor in different cell types, 
by looking for receptor - specific mRNA.
If cellular tropism is not determined by binding to specific membrane proteins, 
then it must be determined at an intracellular level, as with several other virus 
families. Influenza virus for instance, utilizes intracellular proteases to cleave 
and mature haemagglutinin for use during subsequent cycles o f replication.
The obvious step, if  it were to be shown that the HAV host range is determined 
by intracellular mechanisms would be to undertake work to detect the presence 
of intermediates throughout its replicative pathway. This would have to begin 
with the investigation o f whether virus is internalized in the first place, and 
may involve more in depth studies at the cell surface. Herpes Simplex Virus 
for example, bears several membrane glycoproteins but the resulting 
interaction o f the virus with its target cells is not a simple ’binding - 
internalization’ sequence o f events. Instead, one of the virus's glycoproteins 
has been implicated in penetration as a separate event from binding (Johnson et
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al, 1990 ). This could still be the case with HAV. The myristylation status of 
HAV, and its comparison with other picomaviruses (as described in 1.1.6 ) 
may also have an important bearing on internalization, although the 
mechanisms o f picomavirus penetration o f cellular membranes has yet to be 
fully described.
The saturation binding curves described in chapter 3, in conjunction with the 
recent isolation o f the cellular receptor, have also shed light upon the 
interaction o f HAV with permissive cell lines. The linear - linear plot and the 
semi - log plot o f saturation are sigmoid, an indication o f positive 
cooperativity. This observation is reinforced by the close fit o f the data to a 
curve described by the Hill equation, and the inability to fit the data to a linear 
plot for classical Michaelis - Menten - like binding, namely the Scatchard plot. 
Furthermore, the Hill coefficient also suggests that allosteric mechanisms are 
taking place.
A more reliable picture of the saturation of FRhK-4 cells with [125I]-HAV 
would have been established if  more data points had been obtained. 
Unfortunately the quantity o f virus required to completely saturated the 
monolayer and obtain a non-specific binding curve were beyond the capacity of 
the tissue culture facilities available.
Though, initially the mechanisms o f an allosteric interaction are hard to 
envisage, the evidence of Anderson et al (Meeting abstract) that the cellular 
receptor is a homodimer which also binds HAV in its monomeric form, lends 
weight to the suggestion that binding may not be o f a simple nature, as it is not 
uncommon that the binding o f a ligand to a monomer o f a dimeric receptor 
induces a conformational change in the adjacent monomer. There is however 
another possible explanation; HAV has a tendency to aggregate, indicating 
that HAV has an affinity for itself. If one virion has bound to its receptor, 
following Michaelis - Menton kinetics, it is quite possible that its presence 
increases the affinity o f the dimer - virus complex for a second virion, leading
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to apparent positive cooperativity, provided the affinity of virion for virion is 
greater than that o f virion for receptor (see Fig 6.1)
This hypothesis is reinforced by the observation that viruses often exhibit 
changes in structure upon binding to cells, revealing more hydrophobic 
structures (Paul et al., 1987; C howetal., 1987) which in turn would mean 
that a bound virus is even more likely to attract an unbound virus than a free 
virus would. If indeed this increased affinity of free virus was dependent upon 
a structural change in the bound virus, then this interaction would also be 
saturable, as is demonstrated by the results obtained. Unfortunately it is not 
easy to see how this scenario might be disproved, without more information 
about the structure of the receptor.
There are also some artefactual explanations for the shape of the Scatchard and 
semi-log plots. One problem with the Scatchard plot is that if  the original 
preparation of ligand is not pure, and the impurities become radiolabelled, 
then an excess o f non-binding impurities can lead to this type o f plot. This was 
overcome by ensuring that the preparations of virus were very highly purified, 
with SDS-PAGE analysis o f the preparations routinely undertaken; typical 
results are shown in fig. 6.2 and fig. 6.3. Additionally the non-specific binding 
element o f a saturation curve may influence its shape and give misleading 
results. Although a complete estimation o f HAV - non-specific binding was 
impossible due to the constraints o f virus availability, (a monolayer must be 
saturated with cold virus before establishing the extent o f non-specific binding 
with [123I] - HAV) the influence o f a linear non-specific curve on the saturation 
curve obtained could be observed on a purely hypothetical basis. When this 
was done the resulting "specific curve" remained sigmoidal, suggesting that the 
original result obtained was real.
The number o f receptor copies on FRhK-4 cells can be estimated from the 
extrapolated saturation curve, and indicates that there are approximately 1500 
receptors / FRhK-4 cell.
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with 1 ound virion
B
Fig 6.1 Two diagrammatic explanations for the apparent positive cooperativity. 
Example A shows a classic allosteric interaction with the first virion binding to 
a dimeric receptor and, as a result increasing the affinity of the receptor for a 
second virion (K2 > K l). Example B shows a second virion binding to the cell 
receptor via a first virion rather than directly to the cell receptor. This results in 
positive cooperativity if  HAV has a higher affinity for itself than for its cellular 
receptor (K2 > Kl).
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Fig. 6.2 SDS-PAGE analysis o f a typical purification of HAV showing capsid 





Fig. 6.3 SDS-PAGE analysis of [125I] - HAV.
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Iodination « 2.2 x 106 cpm /lp g  o f HAV protein 
=> B = 5031 cpm / 1.25 x 103 cellsmax r
=> Bmax = 2.3 x 10'3 jag of HAV protein / 1.25 x 103 cells 
=> B = 1.75 x 10* virions / 1.25 x 103 cellsmax
=> Bmi = 1380 virions /  cell
This compares with a range o f 103 to 2.5 x 104 for Foot-and-Mouth disease 
virus (Baxt and Morgan, 1986), 3 x 103 to 15 x 103 for rabies virus (Wunner 
and Reagan, 1986), 6 x 103 to 6 x  103 for coxsackievirus B3 (depending on cell 
type) (Hsu et al, 1990) and 3 x 103 for Poliovirus (Mendelsohn et al, 1989). 
An estimation o f the Kd for the interaction can also be given from the S0 5 
calculated by the FigP curve fitting program.
S03 = 47716 cpm {iodination = 2.2 x 10  ^cpm / lug vims }
= 2.17 x 10_2 jig vims protein 
= 1.63 x 10^ virions 
= 2.72 x 10“9pmoles in 200pl 
= 1 .3 6 x l0 ’5 pM 
Vims receptor complex formation
The method vims - receptor complex production for the purification of vims 
cellular receptors has been shown to be successful when the raising of an anti - 
receptor monoclonal antibody proves to be impractical, as with Coxsackievirus 
B3 (Mapoles et al, 1985).
Fig 3.7 illustrates a density shift for [123I] - HAV having been incubated with 
solubilized FRhK-4 cell membranes. Whether or not the protein associating 
with the vims represents a cellular receptor for HAV remains conjecture, 
particularly since the virus - receptor complex recently isolated by Anderson et 
al (Meeting abstract) does not progress as far down a sucrose density gradient 
as the putative virus - receptor complex shown in fig. 3.9 (A) (which may 
represent a vims receptor complex but as part o f a large virus aggregate) Fig. 
3.9 however, also shows a 'shoulder' on the major vims peak (B) which would
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be in approximate agreement with the rate o f sedimentation of the virus - 
receptor complex isolated by Anderson et al (Meeting abstract). To resolve this 
question it would have been useful to repeat the experiment, varying the run 
length and range of sucrose gradient, to see if  peak B could be further 
resolved. Having resolved a peak, then the virus - receptor complex could be 
reiodinated, and the molecular mass o f the receptor established by subjecting it 
to SDS-PAGE. Again, it is important to point out that peak A was obtained 
several times, in efforts to improve the yield o f this peak. (Figs. 3.7 - 3.9). 
Attempts to identify the constituents o f peak A yielded no extra information. 
There was insufficient counts o f bound virus to detect it by SDS-PAGE. 
Subsequent iodinations of the whole of peak A yielded nothing. This was 
probably due to unavoidable losses during the procedure, such as non-specific 
binding to the size exclusion column (even though these columns were 
preblocked with albumen). It is clear that yields must be improved before 
further investigation can take place.
Surface labelling (or in vitro labelling) o f the target cells may improve 
quantities o f purified virus - receptor complex isolated since this would be less 
likely to damage the virus and therefore the virus - receptor interaction.
The next step would be to identify this virus - receptor complex by sandwich 
ELISA (see 2.11) rather than relying on virus iodination. As a result, the 
purified complex could be used as an immunogen for the production of an anti­
receptor antibody, reducing the number o f clones which would have to be 
tested.
These preliminary experiments suggest that this method might be useful for 
receptor isolation. The obvious limitations of the method are that purified virus 
is required, and only small quantities o f cellular receptor can be isolated at a 
time.
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6.2. HEPATITIS A VIRUS - SPECIFIC MONOCLONAL ANTIBODIES.
The neutralization o f viruses by monoclonal antibodies and convalescent sera 
can, in many instances, be extremely complex, with the inhibition of binding 
being one of the more uncommon mechanisms (Dimmock, 1984).
It is thought that Influenza Virus, for instance, is neutralized by the inhibition 
o f transcription. A neutralizing monoclonal antibody may initially bind to the 
virus's envelope glycoprotein, but the neutralized virus is still able to bind to 
the target cell, be internalized and uncoat. The viral transcriptase complex has 
however been altered, and no RNA or viral proteins can be detected. The 
disabling o f the viral transcriptase complex has been shown to occur at the 
point when the antibody binds to the virus haemagglutinin (HA) and remains on 
the cell surface once the virus has been internalized, playing no further part in 
neutralization. The mechanism by which the neutralization is transduced from 
the virus envelope to the transcription complex is not understood (Dimmock, 
1984).
Viruses may also be neutralized by more than one mechanism. Poliovirus for 
example, is probably neutralized by the inhibition of binding, but also by 
mechanisms by which the structure is altered such that the virus pi remains at 
4, which is not compatible with infection o f the host cell (poliovirus varies 
between a pi o f 4 and 7, the latter form being infectious).
The results obtained for HAV suggest that this virus is neutralized by the 
binding o f neutralizing antibodies to the area o f the vims capsid which interacts 
with the target cell, since the ability o f antibody to neutralize the vims 
correlates with its ability to inhibit binding to red blood cells and FRhK-4 cells. 
If this hypothesis proves to be accurate, it would fit the observation that there 
is only one naturally occurring HAV serotype, since to escape a neutralizing 
polyclonal serum would almost certainly prove fatal. As a consequence, this 
would mean that the 'canyon hypothesis' which has been applied to other
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picomaviruses, does not apply to HAV, since to neutralize by this route would 
clearly need an exposed binding site. There are reports o f HAV escape mutants 
which are still viable (Ping and Lemon, 1992), but their ability to bind to cells 
and replicate as efficiently as wild type virus has not been fully investigated, 
so it seems possible that these viruses are not able to compete with wild type 
virus in a mixed population, even if  they do continue to exist in a single 
serotype environment.
Unfortunately, the failure as yet to fully correlate the haemagglutination result 
with the inhibition o f [123I]-HAV binding to FRhK-4 cells means that the 
hypothesis has yet to be confirmed.
The most likely reason why 14H should partially inhibit [123I]-HAV binding to 
FRhK-4 cells but not RBC is that the receptor on non-permissive cells (such as 
red blood cells) and permissive cells (such as FRhK-4 cells) are not the same, 
or are in a different immediate environments, and that cell tropism is still 
determined at the cell membrane, as has been discussed in chapter 6.1.
A situation could be envisaged where the epitope of the non-neutralizing 
antibody, 14H, is close to the neutralization site on the virus capsid and is 
effective in inhibiting binding o f virus to FRhK-4 cells but not red blood cells. 
This probably means that the receptor on red blood cells is more exposed than 
on FRhK-4 cells.
It is also possible that there are two different active binding sites on the virus 
which would allow the virus to bind to different target cells at different binding 
sites. The different optimum [Ca^] and pH may then be explained by the two 
different virus - target cell interactions. It would also have interesting 
ramifications for the pathological mechanisms of the virus since the pH where 
enteroviruses first interact with the host (the intestines) is generally more acidic 
than that o f the intercellular space surrounding hepatocytes.
It may be difficult however, to reconcile this hypothesis with the results 
obtained with MAbs 813 and 10.09, which interfered with the binding o f HAV
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to FRhK-4 cells and red blood cells suggesting that these monoclonal 
antibodies bind to a portion of the virus which interacts with both FRhK-4 and 
red blood cells.
It would interesting to construct HAV saturation binding curves for RBC as this 
would indicate what kind of interaction exists between HAV and RBC. It 
would then allow comparisons with the FRhK-4 cell - HAV interaction.
It must be pointed out that the quantitation of the monoclonal antibodies 
described in section 2.9 suffers at the hands of limited information regarding 
the affinities o f the mAbs 813, 10.09 and 14H for HAV. Though the 
assumption is that the degree o f competition binding relates to the site on the 
virus where the antibodies are binding, (14H competes with [125I]-10.09 less 
than 813 because it is binding to a different area o f the virus capsid), it may 
also indicate different affinities o f the antibodies for the same location.
This could be overcome by gaining some information about the affinities o f 
813, 10.09 and 14H for HAV or by repeating the exercise using [125I]-14H and 
[125I]-813 as the competed antibody to see if  the same conclusions can be 
» drawn.
In addition the quantitation of the mAbs by direct ELISA suffers from the doubt 
as to how much o f the total IgG present in the ascitic fluid preparations is 
directed against HAV and how much is normal murine production. Though 
this could be countered by quantitating the antibody using the sandwich ELISA 
the error is unlikely to be greater than 10% since in general around 90% of 
ascitic fluid IgG is directed against the target antigen. The different monoclonal 
antibody isotypes may also influence the result since the affinity of the 
detecting antibody for different mAbs may vary.
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6.3. INHIBITION OF BINDING
The limited inhibition studies described in Chapter 5 give some insight into the 
structure o f the receptor. The enzyme pretreatment o f the cell surface prior to 
binding assays indicates that the receptor is comprised fundamentally o f 
protein. This is not surprising as the majority of receptors are proteins. There 
are however, exceptions. Influenza virus, as an example, utilizes sialic acid 
as a primary binding site, and though this moiety is often associated with 
proteins, this is not essential. As a result the trypsin pretreatment o f a cell will 
not entirely abolish influenza virus binding. The neuraminidase result obtained 
for HAV, at first appears to suggest that sialic acid does not play a part in virus 
binding (HAV binding remained at 86% after neuraminidase treatment of the 
cell). However, the degree o f removal o f sialic acid was not established. 
Endoglycosidase F treatment of the cell surface was investigated to see if  
removal o f N - linked carbohydrate residues would effect binding, and thus to 
see if  the HAV receptor was indeed a glycoprotein. Initially it would appear 
that this is not the case, but the ability o f this enzyme to cleave effectively 
when a protein is folded is doubtful. This result therefore must be viewed with 
considerable caution.
The degree of enzyme digestion of the cell surface could be tested in two ways. 
Viruses or other ligands known to bind to certain moieties could be used in 
binding assays. Influenza virus for instance could be utilized to quantify the 
degree of removal o f sugars from the cell surface by endoglycosidase F and 
neuraminidase whilst Rhinovirus or Poliovirus could give an indication of 
protein digestion by trypsin.
Assaying for peptides and reduced sugars in the cell supernatant would also 
allow quantitation o f the degree of degradation.
Given sufficient [125I]-HAV a time course o f binding against time of enzyme 
treatment would also confirm the results obtained.
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The haemagglutination inhibition studies, though never intended to represent a 
definitive study o f the possible components o f the cellular receptor, are a 
relatively simple screening assay to determine whether certain compounds 
affected binding o f virus to red blood cells. The lectin studies at first sight 
appear to lend evidence to the argument that sugar residues may play an 
important role in binding, and more specifically, suggest that the less 
common fucosylation of oligosaccharides may be particularly relevant. The 
subsequent use of thyroglobulin (a glycoprotein known to bear fucosylated 
oligosaccharides), and free L - fucose, to inhibit haemagglutination was an 
attempt to confirm these results. The results o f these experiments did fit the 
hypothesis, with low concentrations o f thyroglobulin inhibiting 
haemagglutination. The inability o f fucose to affect binding was not surprising, 
considering its small size. These results could be complemented with the use 
o f more specific enzymes to specifically remove fucose, such as fucosidase. 
The well documented effect o f foetal calf serum on binding ( again confirmed 
here) also reinforced this conjecture, since foetal calf serum contains several 
glycoproteins bearing fucose. However, when confirmation o f these results 
was sought after in the more applied environment o f the binding assay, the 
Lotus lectin (specific for fucose) failed to inhibit binding as conclusively as in 
the haemagglutination assay. Due to lack of available virus and the constraints 
of time, it was not possible to perform a dilution series to indicate whether or 
not the virus was saturated by the lectin solutions which were incubated with 
the virus.
There remains the possibility that the receptor for HAV on non-susceptible cell 
lines (such as red blood cells) and permissive cells (such as FRhK-4 cells) are 
not the same, or are in different immediate environments. One difference may 
be that fucose only plays a part in binding to red blood cells and may have a 
bearing on why HAV binds but does not infect certain cell lines. Table 6.4
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Red Blood Cells FRhK-4
pH 5.5 7.4
[Ca~] Not needed Essential
Non-neutralizing 
antibody, 14H
No effect Some effect
Fucose-specific lectin Inhibits HA No effect
Table 6.4 Summary of differences between interaction of HAV and red blood 
cells and FRhK-4 cells.
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summarizes this and other notable differences between binding of HAV to 
FRhK-4 and red blood cells.
Again it is worth noting the possibility of two separate binding sites on the 
vims capsid which may interact with two different sites on FRhK-4 and red 
blood cells ( as has been mentioned previously). This scenario, of course 
would probably give very different results in a study of this kind because 
different moieties on the different cell surface would be involved in binding the 
vims.
It would also be useful to look at the effects of these conditions on the binding 
of HAV to other susceptible cell lines such as CHO and WRC cells to see if  
any correlation arises. Equally important would be to repeat the saturation and 
temperature analysis with non-susceptible cell lines to identify any other 
differences such as receptor affinity. It may then be possible to draw some 
conclusions as to why HAV binds to certain cell lines but does not (apparently) 
infect them.
The prevailing problem that existed with binding studies with HAV, is the 
virus's well documented susceptibility to aggregation and non - specific 
interactions with proteins. As a result, the haemagglutination inhibition 
studies must be taken as a preliminary investigation, but must also be backed 
up with more in depth work involving binding to susceptible cell lines. It must 
also be borne in mind that lectins are large polypeptides, and their effect on 
binding may come as a result of general steric hindrance of the binding site, 
rather than specific interference with certain sugar residues.
6.4 CONCLUSIONS
The production of usable quantities o f HAV represented a problem throughout 
the project. A problem that hampers most workers in the field of HAV 
research. Attempts to improve the yields of vims included switching briefly to 
BS-C-1 cells as the host, an approach favoured by many workers who claim
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that this cell line gives better cytopathic effect with the HM175 strain of HAV. 
In our hands however there was no improvement in virus yields and indeed 
HAV - mediated plaques were first experienced with the FRhK-4 cell line. 
Attempts to move production into roller bottles with the resulting vast increase 
in cell monolayer area also afforded nothing as the cells did not grow 
efficiently. Indeed the behaviour of FRhK-4 cells in roller bottles was so 
unexpected that mycoplasma testing via the Hoechst stain was instituted to try 
an explain it. This gave negative results whenever used.
It is a running theme throughout the project, particularly with the saturation 
curve analysis that an increased availability of HAV antigen would have 
improved the quality of results obtained.
However, certain definite conclusions can still be made. The receptor is 
certainly a protein. This has been shown both by the interference o f binding by 
trypsin treatment of the target cell, and by the staining of the non - viral 
portion of the virus receptor complex isolated by Anderson et al, (Meeting 
abstract). The role of protein associated moieties unfortunately remains 
extremely vague. This however can be probed, given time and sufficient virus, 
using the methods outlined above, namely inhibition of haemagglutination by 
any number of compounds and lectins as a general screen, followed by 
application of the same methods for virus binding to FRhK-4 or BS-C-1 cells. 
Enzyme treatment o f red blood cells, FRhK-4 and BS-C-1 cells would also 
provide valuable information.
The saturation of a monolayer of FRhK-4 cells with virus indicates that the cell 
surface can be saturated, that the receptor copy number is not high, and that 
mechanisms of positive cooperativity are taking place as a result of an allosteric 
interaction at multiple sites on the receptor. This finding appears to support the 
findings of Anderson et al (Meetings abstract) that the receptor may exist as a 
dimer. The binding tropism o f the virus has yet to be confirmed, inasmuch as 
a specific interaction o f vims with cell lines unable to support its replication
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has not been shown. Again, resolution of this question does not present any 
complicated technical problems. Saturation of a monolayer of such a cell line 
would be sufficient to show the interaction to be specific. If this proved to be 
the case, far more work would be required to discover what determines which 
cell types the virus will infect.
Although the non-neutralizing antibody reduced HAV binding to around 10%, 
the results obtained with the neutralizing antibodies strongly suggest that the 
virus is neutralized at its cell binding site.
It is still important to try and produce a cell receptor monoclonal antibody, for 
at least two reasons. Firstly, a monoclonal antibody would allow a large scale 
purification of the receptor and subsequent in depth investigation of its 
structure. Secondly, although eventually the binding tropism of the virus in 
tissue culture will be described, it may not be possible to relate the results to 
an in vivo situation. A monoclonal antibody to the receptor, conjugated to an 
appropriate label, could be used in immunocytochemical analysis of tissue 
samples to identify which human cells the vims may infect; assuming, of 
course that there is a correlation between the possession o f a specific cell 
surface receptor and the infection of that cell.
In short, there is still a great deal of work to be done on the infection of cells 
by HAV, but with the progress that has been made in this area of research it 
seems certain that many of the outstanding questions will soon be answered.
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